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Abstract 
Infection of host tissue is commonly initiated by adherence of pathogenic bacteria, such 
as Pseudomonas aeruginosa, to cell surface membrane proteins, sugars or lipids. One 
class of proteins known to play a major role in cellular processes, such as adhesion are 
tetraspanins, specifically CD9, CD81 and CD151. Prevention of adhesion could provide 
a new therapeutic strategy for treating infectious diseases. This work aims to investigate 
the potential of using recombinant tetraspanin extracellular domains (EC2), anti-
tetraspanin antibodies and CD9 EC2-derived peptides as anti-adhesives in treating P. 
aeruginosa infections. Also, to create a new higher throughput method to measure 
bacterial adhesion using flow cytometry.  
Expression profiles of different tetraspanins in human epithelial cell lines, A549, HEC1B 
and keratinocyte HaCaT cells were visualised using immunofluorescent microscopy and 
quantified using flow cytometry. Monolayers of adherent cells were pre-treated with the 
tetraspanin reagents (EC2: GST recombinant proteins, anti-tetraspanin antibodies and 
CD9 EC2-derived peptides), before infection with GFP-labelled P. aeruginosa (PAO1) 
for 60 minutes. Bacterial adhesion was determined by counting the number of bacteria 
per infected cells with fluorescence microscopy. Analysis revealed the anti-adhesive 
properties of these tetraspanins (anti-tetraspanin antibodies and recombinant proteins).  
In conclusion, a flow cytometry method was developed but was found to be too un 
sensitive to measure changes in bacterial adhesion. Moreover, anti-tetraspanin antibodies, 
recombinant proteins and CD9 EC2- derived peptides may have the potential to inhibit 
adherence of P. aeruginosa. This work has identified a role for tetraspanins in bacteria-
host cell adhesion, and the possible use of tetraspanin reagents as therapeutics for treating 
P. aeruginosa infection. 
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1.1 Tetraspanins 
Tetraspanins are a family of transmembrane proteins, of up to 350 amino acids, with 
molecular weights ranging from 20-50 kDa. Since their discovery in the early 90s in 
human melanoma cells (Wright and Tomlinson, 1994; Maecker et al., 1997), they have 
been found in all cell types apart from red blood cells (Boucheix et al., 2001). 
Tetraspanins are integral membrane proteins that associate with different types of proteins 
through which they mediate cellular processes such as fusion, adhesion, invasion, tissue 
differentiation and immunological responses through different molecular signalling 
(Hemler, 2003; Hemler, 2005; Levy and Shoham, 2005b; Tham et al., 2010; Hong et al., 
2012). In humans, 33 of these proteins have been identified with varying expression in 
different cell types as well as in other eukaryotic organisms like protozoans, fungi and 
plants (Fanaei et al., 2011; DeSalle et al., 2013). 
1.1.1 The structure of tetraspanin proteins 
All tetraspanins have a similar structural pattern, which consists of four hydrophobic 
transmembrane domains (TM1-TM4) with cytoplasmic and extracellular loops (Figure 
1.1). The four transmembrane domains forming two extracellular loops (EC1 with 
between 20 to 28 amino acids and EC2 with between 76 to 131 amino acids) and one 
cytoplasmic loop (Maecker et al., 1997; Huang et al., 2010). The N and C termini, 
typically short sequences of amino acids that may be longer in some members, are located 
on the cytoplasmic side of the membrane. The EC2 loop, also called the large extracellular 
loop (LEL), is larger than EC1 which is also referred to as short extracellular loop (SEL), 
and contains a constant region with 3 highly conserved α-helices and a hypervariable 
region with between 2 and 4 disulphide linkages that are essential for almost all 
tetraspanin interactions (Seigneuret et al., 2001; Hemler, 2005). The TM1, TM3 and TM4 
  3 
domains also contain polar residues of unknown functions and a number of post 
translational modification sites, usually palmitoylation on cysteine residues within the 
transmembrane regions (Stipp et al., 2003; Levy and Shoham, 2005b).  
 
 
Figure 1.1 A schematic representation of tetraspanin structure.  
Tetraspanins are composed of four trans-membrane (TM) domains (green cylinders) and contain 
conserved amino acid sequences. TM1 and TM2 flank the short extracellular loop (SEL), whereas 
TM3 and TM4 flank the long extracellular loop (LEL). Shown here is the conserved cysteine-
cysteine-glycine (CCG) motif in the LEL, which forms disulphide bridges with additional 
conserved cysteine residues (C). Also highlighted here are the conserved cysteine residues in the 
amino (NH2) and carboxy (COOH) terminal regions and the inner loop of the intracellular portion 
of the molecule. Adapted from Levy and Shoham, 2005.  
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1.1.2 Tetraspanins mediate protein-protein interactions and play roles in 
infectious diseases 
There are now several pieces of evidence that tetraspanins have a major role in the lateral 
arrangement of cell membrane proteins (Boucheix et al., 2001; Hemler, 2003; Hemler, 
2008; Charrin et al., 2009). Tetraspanins interact with different proteins including other 
tetraspanins in a tetraspanin-tetraspanin interaction, or with receptors and other signaling 
proteins to make up a functional complex at the cell surface, called a tetraspanin enriched 
microdomain (TEM) (Hemler, 2003; Wright et al., 2004; Charrin et al., 2009). This 
consequently leads to the involvement of tetraspanins in several cellular processes, 
including differentiation, proliferation, migration and invasion in both malignant and 
infectious diseases (Hemler, 2003; Wright et al., 2004; Zoller, 2009). New insights into 
tetraspanin protein-protein interactions and microdomain compositions have shown TEM 
to be dynamic in nature, conferring on cells the ability to adapt to their constantly 
evolving environment (Barreiro et al., 2008; Espenel et al., 2008). This may also explain 
why most tetraspanin interactions with other proteins are temporary or weak. 
It is evident that the interaction between tetraspanins and their partner molecules results 
in the formation of functional units. For instance, CD151 (tetraspanin) interacts with 
integrins α6β4, α5β1 and α3β1 to regulate integrin-dependent cell migration, motility and 
strengthening of adhesion. This is done in part by regulating the trafficking of these 
integrins across the cell membrane through the modulation of endocytosis and vesicular 
trafficking of these CD151-associated integrins (Liu et al., 2007). Patients that harbour a 
mutation in the CD151 integrin binding domain are known to suffer skin blistering and 
hereditary nephritis (Karamatic Crew et al., 2004). CD9 and CD81 associates with CD9P-
1, an immunoglobulin domain molecule, to maintain muscle regeneration ability. Mice 
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lacking these two tetraspanins lose the ability to regenerate muscles through the formation 
of huge dystrophic myofibres that are formed more rapidly in mice lacking both 
tetraspanins (Charrin et al., 2013). These studies demonstrate that dysfunction or lack of 
tetraspanin expression can lead to the development of various phenotypic defects. 
Interestingly, deficiency of the human CD53 protein has been associated with chronic 
infectious diseases caused by viruses, bacteria and fungi (Mollinedo et al., 1997). 
Tetraspanins functionally interact with known immune receptors including protein 
constituents of B cell receptor complex, MHC molecules, C type lectins (selectins) and 
integrins. As such, tetraspanins are able to modulate the immune system through receptor 
signalling and regulate proliferation of leukocytes, antigen presentation and cytokine 
expression.  
1.1.2.1 The role of tetraspanins in viral infections 
Viruses are obligate intracellular parasites, relying on the host cell machinery for survival 
during various stages of their life cycle in order to cause infection (Hemler, 2008). 
Tetraspanins have been shown to play important roles in the pathogenesis of intracellular 
pathogens such as viruses by enhancing the life cycle and the ability to invade and 
colonise host cells. For instance, some viruses use TEM to facilitate entry into host cells 
and to infect other cells (Dahmane et al., 2014). As such, tetraspanins play important role 
in the pathogenesis of many viruses considering the poor infectivity of viral particles. 
1.1.2.1.1 Tetraspanins and HIV infection 
Tetraspanins take part in the pathogenesis of HIV-1 infection, which is responsible for 
the development of AIDS. HIV-1 infects mainly CD4+ T-cells and also other antigen 
presenting cells such as macrophages and monocytes. It acts by primarily binding to CD4 
  6 
on target cells to gain entry into the host cells, and subsequently binds to CCR5 or 
CXCR4, which are chemokine receptors (Martinez-Munoz et al., 2014). Afterwards, 
there is the internalisation of the virus by endocytosis or by cell fusion at the cell surface. 
This allows the virus to replicate its genetic material using the host replicating machinery. 
The first indication that tetraspanins play a role in the pathogenesis of HIV-1 was the 
discovery in H9T cells that CD63 selectively co-localises at budding structures and newly 
formed HIV-1 virions (Meerloo et al., 1992). Usually, during HIV infection, there is cell-
cell adhesion or fusion between uninfected and infected cells leading to transmission of 
viral material and subsequent separation. These cells could otherwise form what is known 
as a syncytium. CD9 and CD63 have been recently shown to negatively regulate the HIV-
1 induced cell-cell adhesion by inhibiting the transmission from hemifusion of the cells 
to opening of the pore for viral particle transfer (Symeonides et al., 2014). Conversely, 
CD63 was shown to support Env mediated cell-cell fusion through CCR5 and CD4 as 
CD63 siRNA treated R5X4-tropic HIV-1 strains had marked inhibition in infectivity 
while the MLV or VSV-pseudotyped strains expressing an NL4-Env protein did not show 
inhibition of infectivity (Li et al., 2014). This suggests that infection of non-infected cells 
may be cell type dependent, probably due to alternative pathways for regulating 
infectivity at the hemifusion stage. In addition, CXCR4 is a coreceptor like CCR5, and it 
is required in the alternative pathway of HIV infectivity because it allows adhesion of 
infected cells with new host cells when binding through CCR5 is prevented. As such, 
there is CCR5 or CXCR4 tropic HIV infection. Interestingly in IL-21 activated B cells, 
CD63 was shown to inhibit the expression of CXCR4 by increasing endocytosis of 
CXCR4, which is activated by the increased expression of GRK6, an endocytosis related 
molecule in CD4+ T cells (Yoshida et al., 2011).  
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1.1.2.1.2 Hepatitis C virus 
The role of tetraspanins in the pathogenesis of viral infections has been widely 
documented and one of the initial findings was the identification of CD81 as a receptor 
for HCV (Pileri et al., 1998). HCV is the major cause of liver disease and is also 
associated with cryoglobulinaemia, a B lymphocyte proliferative disorder. HCV has two 
envelope glycoproteins, E1 and E2, which are covalently linked as a dimer (E1E2) and 
both glycoproteins are required for virus binding and host cell invasion (Op De Beeck et 
al., 2004). It has been demonstrated that palmitoylation of cysteine residues on CD81 
plays an important role in protein-protein interactions in TEM and in association with 
cholesterol-rich domains of membranes. Inhibition of this modification of CD81 reduces 
its interaction with other tetraspanins and thus reduces infectivity of the host cell by HCV 
(Zhu et al., 2012). It was recently demonstrated that EWI-2wint, an inhibitor of HCV 
during cell entry reduced the mobility of CD81 by encouraging its confinement and 
concentration at enriched areas, making it unavailable for HCV entry into target cells 
(Potel et al., 2013). Thus, changes in the dynamics properties of CD81 are utilised by 
HCV in the presence of a natural inhibitor to favour target cell invasion. 
1.1.2.1.3 Tetraspanins in other viral infections 
Apart from HIV and HCV pathogenesis, tetraspanins have also been demonstrated to play 
key roles in several other viral infections. HTLV-1 is the causative agent of adult human 
T-cell leukaemia, which uses CD4+ and CD8+ T cells as its viral reservoir (Jones et al., 
2006). The infection caused by the virus is likely through cell-cell interaction as virions 
are usually of poor infectivity and tetraspanins have been shown to maintain cell adhesion 
and fusion in viruses (Hemler, 2003). Tetraspanins associate with laminin-binding 
integrins and are instantly sequestered in immunological synapses formed between 
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antigen presenting cells. T-cells and B-cells predominantly express CD82 as the major 
tetraspanin on their surface and it has been demonstrated that during HTLV-1 infection, 
the HTLV-1 virion through its Gag protein interacts with CD82 containing tetraspanin 
microdomain to facilitate sequestration of newly formed virions to sites of cell-cell 
interaction (Mazurov et al., 2006). Tetraspanins have also been shown to be involved in 
the pathogenesis of human papillomavirus type 16 (HPV16) which is linked to the 
development of cervical cancer (Cornet et al., 2013). HPV16 is a non-enveloped virus 
possessing a double stranded DNA molecule and binds to host cells via a heparan sulphate 
proteoglycan such as syndecan-1 (Letian and Tianyu, 2010). Prior to its internalisation 
via an endosome, HPV16 that is bound to the cell surface binds to CD151 moving along 
the plane of the cell membrane. This was demonstrated in a study by Scheffer et al., 
(2013) where CD151 depleted cells showed reduced internalisation of HPV16. In this 
study, it was also shown that CD151 associated integrins (α3β1 and α6β1/4) are 
responsible for the HPV16 infection. 
1.1.2.1.4 Tetraspanins and bacterial infections 
The defence mechanism of a host to bacterial infection is usually associated with bacterial 
surface structures and its mode of infection (Smith, 1977). Gram-negative bacteria are 
destroyed by complement factors or cytotoxic cells through cell wall lysis while Gram-
positive bacteria or mycobacteria require specialised phagocytic cells such as neutrophils 
and macrophages. During infection, the activation of the humoral immune system results 
in antibody production by B-cells while cellular immunity is elicited by T-cells. Some 
bacterial species, however, have developed techniques to evade the cellular defence 
mechanisms of the host, some of which involve the alteration of cellular immunity and 
immune signalling, invasion of the host cell, and neutralisation of immune mediator 
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actions, most of which involve cell-cell interaction. Adhesion of bacteria to host tissues 
also provides resistance to mechanical methods of bacterial clearance such as mucus and 
tears  (Pierre et al., 2016). 
1.1.2.1.4.1 Escherichia coli (E. coli) 
Uropathogenic E. coli (UPEC) is the major causative agent for urinary tract infections 
(UTIs) and the only documented direct interaction between a bacterium and tetraspanin 
is that between UPEC and uroplakin 1a (Svanborg and Godaly, 1997). The pathogenesis 
of UTI begins with the binding of UPEC to the epithelia of the bladder through the 
interaction between a bacterial adhesion molecule, FimH adhesin, and uroplakins on the 
epithelial lining of the urinary tract (Wu et al., 1996; Kątnik-Prastowska et al., 2014). 
Uroplakin la (Tetraspanin 21) and uroplakin lb (Tetraspanin 20), together with uroplakin 
2 and 3a form a receptor complex which is assembled into a crystal-like structure covering 
most of the epithelia of the urinary tract (Wang et al., 2009). Through this structure, FimH 
adhesin binds to the epithelial surface to enable adhesion of UPEC. Through this 
mechanism, UPEC can bind to deeper layers of the bladder with the help of other 
tetraspanins like CD63 to remain in a quiescent state until the bladder becomes filled 
whereupon the bacteria become active. It has also been shown that tetraspanin CD82 
plays an important role in the formation of phagosomes containing E. coli and 
Staphylococcus during infection (Artavanis-Tsakonas et al., 2011).  
1.1.2.1.4.2 Listeria monocytogens (L. monocytogenes) 
L. monocytogenes is a Gram-positive bacteria that is the causative agent for listeriosis 
(Williams et al., 2012) L. monocytogenes invades epithelial cells through interaction with 
E-cadherin and hepatocyte growth factor receptor, Met. Type II phosphatidylinositol 4-
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kinase alpha and beta (PI4KIIα and PI4KIIβ) were both identified as required for entry of 
the bacteria downstream of Met through their interactions with CD81 (Pizarro-Cerda et 
al., 2007; Tham et al., 2010; Martinez del Hoyo et al., 2015). Tham et al. , (2010) showed 
that the tetraspanins CD81, CD63 and CD9 are all expressed on the cell surface and co-
localise with PI4KIIα at the bacterial entry site. Through live cell imaging techniques and 
siRNA depletion of these tetraspanins, they confirmed that CD81 is required for 
internalisation of the bacteria into target cells.  
1.1.2.1.4.3 Neisseria meningitidis (N. meningitidis) 
N. meningitidis is a Gram-negative bacterium that resides in the nasopharynx without any 
symptoms; the bacteria has been reported to be present in about 15 % of adults. It is the 
causative agent for meningococcal disease and the main cause of bacterial meningitis 
(Tunbridge and Read, 2004). Through antigenic and phase variation of molecules like 
adhesins and invasins, the bacteria is able to bind epithelial cells which aids 
internalisation (Hill et al., 2010). It has been shown that tetraspanins play an important 
role in bacterial colonisation during initial stages of N. meningitidis infection. When cells 
infected with N. meningitidis were treated with anti-CD63, anti-CD9 and anti-CD151 
antibodies, adhesion of the bacteria to target epithelial cells was greatly inhibited (Green 
et al., 2011a). CD63, CD151 and CD9 were demonstrated to be responsible for the 
adhesion of bacteria to target cells because incubation of the cells with antibodies against 
these tetraspanins (anti-CD63, anti-CD151 and anti-CD9) or incubation with recombinant 
proteins containing only EC2 domain of these tetraspanins resulted in similar results. 
Furthermore, it is becoming increasingly clear that cells treated with anti-tetraspanin 
antibodies experience reduced adhesion with some bacteria such as Staphylococcus 
aureus, N. lactamica, E. coli and Streptococcus pneumoniae (Green et al., 2011a; Monk 
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and Partridge, 2012). 
1.1.2.1.4.4 Staphylococcus aureus (S. aureus) 
S. aureus is a Gram-positive coccus that colonises the skin, nasal epithelium and 
respiratory tract. It is the causative agent of folliculitis, cellulitis and impetigo (Johnson 
et al., 2016). S. aureus is able to access the tissues through a break in the epidermis and 
once it colonises the skin, S. aureus causes skin and soft-tissue infections (SSTIs), such 
as itchiness and necrotizing fasciitis (Hersh et al., 2008). Like most bacterial skin 
pathogens, S. aureus invades epithelial cells through fibronectin binding protein (FnBP) 
(Arrecubieta et al., 2008). In addition, the bacteria can also penetrate deeper into tissues 
from where it can pass into many areas of the body and then causes systemic infections 
(Blot et al., 2002).  
As mentioned in section 1.1.2.1.3.1, anti-tetraspanin antibodies and EC2 proteins were 
found to be able to reduce S. aureus adhesion to host cells, and more recently, it was 
found that the short peptides derived from the EC2 domain of CD9 also could reduce S. 
aureus adhesion to epithelial cell lines, primary keratinocytes and 3D tissue engineered 
model of the human skin (Ventress et al., 2016). 
1.2 Pseudomonas aeruginosa  
Pseudomonas aeruginosa is a rod-shaped, aerobic Gram-negative bacterium, and an 
opportunistic pathogen associated with an array of life threatening infections that occur 
in cystic fibrosis (CF) patients, UTIs, blood stream infections, pneumonia and surgical 
site infections (Fujitani et al., 2011; Lechtzin et al., 2011; Dai et al., 2013), as well as in 
immunocompromised patients (Afessa and Green, 2000). P. aeruginosa accounts for 
between 11 to 13.8 % of all known nosocomial infections and in the intensive care unit, 
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it is responsible for 13.2 to 22.6 % of reported nosocomial infections (Pittet et al., 1999; 
Kim et al., 2000; Lizioli et al., 2003; Erbay et al., 2003; Weinstein et al., 2005). In 
addition, P. aeruginosa accounts for up to 50 % of the mortality in patients that are 
mechanically ventilated (Giantsou and Manolas, 2011)  and is the leading cause of 
morbidity in patients with diseases such as CF and chronic obstructive pulmonary 
diseases (COPD) (Gallego et al., 2014).  
1.2.1 Virulence factors and disease pathogeneses of P. aeruginosa 
P. aeruginosa produces a varying number of the virulence factors that are responsible for 
the pathogenesis of the clinical diseases involving P. aeruginosa. Analysis of the roles of 
different virulence factors from various animal models has increased the understanding 
of disease pathogenesis. It is worthy to note that the pathogenesis of P. aeruginosa is 
related to the precise crosstalk between a host of virulence factors, extending from 
effective colonisation and biofilm formation to tissue invasion, necrosis and or 
dissemination of the pathogen via the vascular system that may result in systemic or local 
inflammatory responses. These virulence factors are either intracellular or extracellular 
based on localisation and the mechanism of action, and the physical relation to the 
bacterium. Extracellular factors are classified according to their secretion mode into the 
type I, II and III secretion systems. The type I secretion system (T1SS) is an ABC-
exporter system that relies on AprD, an ATP binding cassette (ABC) protein; AprE, a 
membrane fusion protein and AprF, an outer membrane protein (Duong et al., 2001). In 
P. aeruginosa, this system secretes HasAp, a haeme-binding protein required by the 
pathogen for haemoglobin utilisation, it also secretes AprX, which is a member of the 
ABC exporter system and alkaline phosphatase (Duong et al., 2001).  
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1.2.1.1 Quorum sensing regulation of virulence in P. aeruginosa 
1.2.1.1.1 Effectors of the T2SS and the T3SS systems 
Components of the quorum sensing system (discussed below) have been shown to be 
important in invasion and biofilm formation in P. aeruginosa pathogenicity (Yang et al., 
2017). P. aeruginosa is known to have five secretory systems but the type II secretion 
system (T2SS) and the type III secretion systems (T3SS) are the major toxins producing 
systems. The majority of P. aeruginosa virulence factors are produced by the T2SS such 
as exotoxin-A (PA1148), alkaline protease (PA1246), the LasA protease (PA1871) and 
LasB elastase (PA3724). The LasA and LasB elastases are controlled by the N-Acyl 
homoserine lactones (AHL) system (see section 1.2.3.1.) and are regarded as the most 
important factors in acute infections. They are both involved in the degradation of elastin 
in human lung tissue and in the vasculature via their elastolytic activities (Galloway, 
1991). The exoproteins that are produced by the T2SS elicit a pathological response when 
in contact with eukaryotic cells and at a distance from the site of infection using quorum 
sensing (Figure 1.2). 
The type III secretion system (T3SS) on the other hand produces virulence factors such 
as the exoenzyme S (ExoS), exoenzyme T (ExoT), exoenzyme U (ExoU) and exoenzyme 
Y (ExoY), all of which require close contact with the target cells in order to elicit 
cytotoxic effects (van Delden, 2004; Juan et al., 2017). This system uses a transmembrane 
syringe-like structure, the "injectisome" to introduce toxins into mammalian cells 
(Quinaud et al., 2005; Engel and Balachandran, 2009). Of the virulence factors secreted 
via the T3SS pathway, ExoS and ExoT have been of most interest in P. aeruginosa 
pathogenicity. It has been reported that a significant proportion of clinical isolates 
produces ExoS (Feltman et al., 2001; Vareechon et al., 2017). Although both ExoS and 
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ExoT are not secreted by the same strain of P. aeruginosa, they are both involved in the 
development of chronic and acute infections (Shaver and Hauser, 2004). The activities of 
ExoS and ExoT have been elucidated in infections like keratitis and corneal ulcers and 
their activities in these infections are dependent on ADP ribosyltransferase expression. 
ExoS and ExoT have been shown to aggravate these infections by promoting neutrophil 
apoptosis through impairment of the pro-apoptotic processes in neutrophils. Their 
activities also promote bacterial survival by impairing the anti-bacterial activities of 
neutrophils (Sun et al., 2012). The delicate interplay between these virulence factors is 
important in the pathogenesis of P. aeruginosa infection and this complex interplay is 
still not fully understood to date. 
Evidence for a possible link between the T2SS and T3SS for coordinated infectivity has 
been documented in the literature. In a study by Cowell et al., (2003), P. aeruginosa 
containing mutant lasA and/or lasB genes showed an increase in the basal levels of ExoS 
and ExoT, which are the T3SS proteins/toxins that inhibit the invasion of the bacteria in 
the host cell. The increased expression of the T3SS proteins also correlates with a 
reduction in invasion of the bacteria in a host cell. This suggests that LasA and LasB 
possibly induce invasion by repressing the expression of ExoS and ExoT expression. This 
repression allows the biosynthesis of different virulence factors required for host cell 
attachment and invasion. Although the mechanism by which LasA and LasB regulates 
ExoS and ExoB is currently not clear, the expression of ExoS and ExoT is controlled by 
ExsA, which is the transcriptional activator for ExoS and ExoT (Cowell et al., 2000), and 
as such LasA and LasB may regulate expression of these toxins through ExsA.  
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1.2.2 Pathogenicity of P. aeruginosa 
Communication between cells mediated by different signalling molecules enables 
bacteria to trigger orchestrated responses in a way that achieves infectivity (acute or 
chronic) in host cells. In P. aeruginosa, the signalling pathway regulating infection is 
perhaps one of the most complex ones known to date. In most Gram-negative bacteria, 
especially in P. aeruginosa, N-Acyl homoserine lactones (AHLs) are the major cell to 
cell signalling molecules used in controlling the expression of several genes in a process 
known as quorum sensing (Withers et al., 2001). AHLs are comprised of a fatty acid of 
varying chain length with an amide bond linking it to a homoserine lactone unit. AHLs 
are synthesised by the LuxI family of proteins and they bind to LuxR family receptors 
(transcriptional factors) forming a complex that binds to the DNA, thus regulating the 
transcription of several virulence genes (Table 1.1).  
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Table 1.1 Some virulence factors of P. aeruginosa. 
. 
PA position Gene name Description References 
PA4528 piLD Motility and attachment (Beatson et al., 2002, Stover et 
al., 2000) 
PA0410 pill Motility and attachment (Köhler et al., 2000) 
PA4554 pilYJ Motility and attachment (Choi et al., 2002) 
PA0762 algU Sigma factor (Wagner et al., 2003) 
PA4446 algal Secretion of alginate (Firoved and Deretic, 2003) 
PA0765 macC Transcription regulator (Govan and Deretic, 1996) 
PA1248 ETV Alkaline protease (Wilhelm et al., 1999) 
PA3478 rhiB Rhamnosyl transferase (Davey et al., 2003) 
PA3831 pepA Leucine amino peptidase (Govan and Deretic, 1996) 
PA5112 estA Esterase (Govan and Deretic, 1996) 
PA5449 wbp Glycosyl transferase (Daniels et al., 2002) 
PA3841 exoS Exoenzyme S (Okuda et al., 2012) 
PA0044 exoT Exoenzyme T (Aiello et al., 2010) 
PA1871 lasA Elastase A (Murray et al., 2010) 
PA3724 lasB Elastase A (Murray et al., 2010) 
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1.2.2.1 The Quorum Sensing System 
In P. aeruginosa, there are two AHL systems, the Las and Rhl systems. The Las system 
produces N-3-oxo-dodecanoyl homoserine lactone (3-oxo-C12-HSL) by the LasI synthase 
(PA1432), and P. aeruginosa responds to the molecule via the LasR (PA1430) 
transcriptional factor (Passador et al., 1993; Pearson et al., 1994). Through this system, 
the bacteria control interaction with host cells, acute infection and host cell damage by 
regulating expression of T2SS virulence factors (Gambello et al., 1993; Passador et al., 
1993; Jones et al., 1993). The Rhl system produces N-butanoyl homoserine lactone (C4-
HSL) by Rhl1 synthase and senses the molecule through the RhlR transcriptional factor 
(PA3477). Both the Las and the Rhl systems function synergistically to produce several 
virulence factors like the rhamnolipids, staphylolytic proteases, exotoxin A, pyocyanin 
and lectins (Smith and Iglewski, 2003; Bjarnsholt and Givskov, 2007). The timely 
orchestration of the biosynthesis of these virulence factors is essential for P. aeruginosa 
pathogenicity. For instance, production of rhamnolipids in the later stages of biofilm 
formation helps to maintain the biofilm architecture (Davey et al., 2003).  
Phospholipase C is expressed in different organisms playing diverse roles in cellular 
biology. For instance, in L. monocytogenes it enhances infectivity of the bacteria in 
eukaryotic hosts while the homologue of phospholipase C expressed by Clostridium 
perfringens is the main cytotoxic agent involved in the pathogenesis of gas gangrene 
(Awad et al., 1995; Marquis et al., 1997). P. aeruginosa expresses two types of 
phospholipase C, which are the haemolytic (PlcH) and the non-haemolytic (PlcN) 
homologues. Both PlcH and PlcN are secreted via the T2SS system through the outer 
membrane of P. aeruginosa and are both used to hydrolyse the phosphatidylcholine 
component of the host cell membrane, thus resulting in a pathogenic and inflammatory 
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response (Meyers et al., 1992). There also exists some evidence suggesting that the 
hydrolysis of phosphatidylcholine by phospholipase C in the lung surfactant results in 
aggravated lung infection (Lema et al., 2000). Phospholipase C and rhamnolipids are 
believed to work synergistically in breaking down lecithin and lipids, enhancing tissue 
invasion (Van Delden and Iglewski, 1998). Rhamnolipids in this process act as a bio-
surfactant to break down the lipid content of membranes, giving extra access to 
phospholipase C to further breakdown the membrane phospholipid. 
 
 
Figure 1.2 Virulence factors involved in quorum sensing in P. aeruginosa.  
The factors involved in quorum sensing are both cell-associated (involving the type IV 
pili, flagella and adhesins) as well as the extracellular factors produced by T2SS (LasA 
and LasB elastases, alkaline protease and phospholipase C) and T3SS (ExoS, ExoT, 
ExoU and ExoY), and other extracellular factors like rhamnolipids and pyocyanin. The 
quorum sensing system is used to regulate the activities of the virulence factors. Adapted 
from van Delden, 2004. 
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1.2.2.2 Attachment and invasion of P. aeruginosa and disease pathogenesis 
The pathogenesis of P. aeruginosa infections constitutes a complex and multifactorial 
process. Because P. aeruginosa is an opportunistic pathogen, it requires a break in the 
host’s first line of defence such as damage to the mucosal lining or immune suppression 
as seen in HIV patients. The attachment of bacteria is a crucial initial step involving 
complex interactions between host cell receptors present on either the apical or basolateral 
surface of the epithelium and bacterial adhesins. Through the use of epithelial cells 
cultured as a monolayer, which reflects simple epithelial tissue, it has been demonstrated 
that N-glycans on the surface of epithelial cells are important molecules sufficient enough 
to facilitate bacterial binding and subsequent entry as well as the cytotoxicity observed at 
the apical surface of the polarised epithelium (Bucior et al., 2010). On the basolateral 
surface, heparan sulphate proteoglycan (HSPG) is required and sufficient to facilitate the 
binding. Bucior et al., (2010) demonstrated that on the apical surface of cells that are not 
completely polarised (tissue damage model), HSPGs are highly expressed and this leads 
to enhanced binding of P. aeruginosa causing tissue damage.  
In P. aeruginosa, there are two major adhesins that have been discovered so far: the 
flagellum (Chi et al., 1991; Feldman et al., 1998; Engel, 2007) and the type IV pilus (Tfp) 
(Hospenthal et al., 2017). The flagellum is a polymer made up of flagellin that is encoded 
by the fliC gene, although several other genes are involved in flagellum assembly and 
function (Dasgupta et al., 2003). The functions of the flagellum include adhesion to the 
epithelium, swimming motility and formation of biofilm. Monomeric flagellin protein is 
recognised by the immune system either through its binding to Toll-like receptor 5 
(TLR5) present on the cell surface or through cytosolic sensors (Feuillet et al., 2006; 
Balloy et al., 2007; Lightfield et al., 2008; Kofoed and Vance, 2011). The mechanistic 
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details of the interaction between flagella and host epithelium are currently lacking but 
the flagellum cap protein of P. aeruginosa strain O1 (PAO1) has been shown to bind to 
the Lewisx oligosaccharides found in mucins (Scharfman et al., 2001). Since mucins are 
found at high levels on CF epithelial surfaces, this may explain why the bacteria colonises 
CF epithelium coupled to the fact that CF patients have thick and dehydrated mucus that 
makes it difficult for ciliary clearance of the bacteria. In a recent study, Bucior et al., 
(2012) demonstrated that Tfp is required to mediate the binding of N-glycans to the apical 
surface of polarised epithelium while flagella are required for binding of bacteria to the 
HSPGs on the basolateral surface of the polarised epithelium, thus facilitating bacterial 
entry. The binding of P. aeruginosa flagella to heparan sulphate chains on HSPGs at the 
basolateral surface of the airway epithelium also leads to activation of EGFR and 
subsequently PI3/Akt pathway, a process that has been shown to contribute to bacterial 
cytotoxicity (Zhang et al., 2004). 
Tfps are appendages that are polarly localised and comprised of pilin polymers. These 
polymers undergo reversible assembly/disassembly, thus allowing the bacteria to undergo 
what is termed twitching motility, which allows the bacteria to move across solid surfaces 
(Mattick, 2002). Tfps also serve as receptors for phage, they facilitate the initial stage of 
biofilm formation and they function as adhesins to mammalian cells (Engel, 2003). 
Different glycosphingolipids have been identified in different studies as host receptors 
for Tfp mediated cell binding at the apical surface of polarised cells (Saiman and Prince, 
1993; Comolli et al., 1999).  
Tfps are among the first set of factors identified in genetic screens in the search for traits 
necessary for P. aeruginosa biofilm formation through their participation in microcolony 
formation and surface attachment (O'Toole and Kolter, 1998). Chiang and Burrows 
  21 
(2003) demonstrated that although the Tfp adhesive function is required for biofilm 
formation, twitching motility also plays an important role in the biofilm architecture 
development. Bacterial mutants that lack the retraction ATPase PilT (a Tfp Atpase 
response dynamics) have been shown to form thick, undifferentiated biofilms compared 
to those that twitch. In a study by Klausen and colleagues, a more detailed explanation 
about the role of twitching in biofilm formation was provided. They cultured biofilms of 
non-piliated and wild type P. aeruginosa labelled with cyan and yellow fluorescent 
proteins, respectively. They observed the formation of the mushroom-like structure of 
mature microcolonies with the non-piliated cells forming the stalk while the wild type 
cells formed the umbrella above the mutants (Klausen et al., 2003b; Klausen et al., 
2003a). The interesting finding was the distinct spatial separation between the cell types. 
This result suggests that twitching is used by the wild type cells to climb the mutants that 
are non-motile.  
1.2.2.3 Biofilm formation and twitching in P. aeruginosa 
Biofilms represent an important form of growth for bacteria serving as protection in harsh 
environmental conditions. Bacteria, especially P. aeruginosa usually exists encased as a 
colony in a biofilm with each bacterium attached to several others and to a surface through 
a structure made up of extracellular polymeric substances (EPS) (Flemming et al., 2007). 
The EPS in P. aeruginosa is a biopolymer, it contains 2 types of polysaccharides, which 
are the capsular and the aggregative polysaccharides. The capsular polysaccharide is the 
major component of the protective structure on the surface of the biofilm and a prominent 
example is alginate, which is a high molecular weight molecule of β-1,4 linked l-
guluronic and d-mannuronic acids repeats. Another example is levan, a high molecular 
weight molecule of β-2,6 polyfructan. The aggregative polysaccharide confers the biofilm 
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with structural integrity and facilitates interaction within the biofilm (Mann and Wozniak, 
2012). The biofilm is formed as a mushroom-like structure attached to a surface through 
the stalk. A specific bacterium in this biofilm is believed to move through the stalk up to 
the cap through a process known as twitching motility (Mann and Wozniak, 2012). The 
bacteria on the cap structure are further dispersed to non-colonised sites for the formation 
of new biofilm (Figure 1.3). P. aeruginosa at high cell density has been shown to secrete 
EPS and through quorum sensing forms biofilms that aids resistance against antibiotics, 
adverse environmental conditions and the immune system (Sakuragi and Kolter, 2007; 
Zeng et al., 2011). A medical implication is that biofilm associated bacteria on catheters 
or surgical implants use this to their advantage in causing serious infections. 
 
 
 
Figure 1.3 Biofilm formation and growth in P. aeruginosa. 
The stages in biofilm formation involve bacterial attachment to host cell surface followed by 
growth of bacterial colonies when the structure of the biofilm begins to form. After formation of 
a matured biofilm, there is a detachment of cells followed by dispersal to other viable sites for 
attachment of new cells. Adapted from Mann and Wozniak, 2012. 
  23 
1.3 Mechanisms of bacterial adhesion to host cells 
In order to cause infection, the bacterial pathogens need to be in a favourable environment 
in the host where they can thrive. Bacteria reach their favourable environment by adhering 
to specific receptors on the host cell surface. Once the bacteria have adhered, they can be 
internalised by various methods or they can also flourish extracellularly by forming their 
own favourable conditions, such as a biofilm. There are various types of interactions 
(mechanical systems) that could be involved in the adhesion of bacteria to host cells; 
adhesion of bacteria to host cell involves adhesins on the bacterial surface and receptors 
on the host cells surface. Table 1.2 shows some examples of interactions that are involved 
in the adherence of bacteria to host cells and Table 1.3 presents some examples of bacteria 
and the adhesins they use to attach to the host cells. 
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 .asurfacesreceptor interactions in bacterial adhesion to mucosal -Table 1.2 Types of adhesin 
Type of interaction Bacterial adhesin (example) Receptor on epithelial cell (example) References 
Lectin-carbohydrate 
Lectin (type 1 fimbriae) 
Capsule (hyaluronic acid of S.pyogenes) 
Glycoprotein (uroplakin on bladder cells) 
Lectin (CD41 on epithelial cells) 
(Wu et al., 1996a; Cywes et 
al., 2000) 
Protein-protein 
Fibronectin binding proteins (F protein 
of S.pyogenes) 
Fibronectin (fibronectin on respiratory cells) 
(Cue et al., 1998; Hanski and 
Caparon, 1992) 
 
Hydrophobin-protein 
Glycolipid (LTA of S.pyogenes) 
Lipid binding proteins (surface protein 
of Campylobacter spp) 
Lipid receptors (fatty acid binding site in 
fibronectin on host cells) 
Membrane lipids (phospholipids and 
sphingolipids of cells) 
(Sylvester et al., 1996; 
Szymanski and Armstrong, 
1996) 
aadaptive from Ofek, 2003. 
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Table 1.3 Some examples of bacterium adhesin and target surface on the host cell. 
Bacterium Adhesin Target surface Host cell receptor References 
Pseudomonas aeruginosa Type IV pili Respiratory epithelium Asiloganglioside (Saiman et al., 1990; Cacalano et 
al., 1992). 
E. coli (UPEC) 
 
 
 
(EPEC and EHEC) 
Pili (PapG) 
Type 1 pili 
Subunit of pili 
FimH 
T3SS 
Kidney epithelium 
Uroplakine of the bladder 
 
Actin cytoskeleton 
Glycosphingolipids 
D-mannosylated receptors 
Mannose or tetraspanin protein 
uroplakin la 
Cytoskeleton regulators 
(Roberts et al., 1994; Martinez et 
al., 2000; Zhou et al., 2001; 
Sokurenko et al., 2008; Lai et al., 
2013; Lillington et al., 2014). 
Neisseria meningitidis Type IV pili 
Opc (opacity 
protein c) 
Tfp 
Vascular endothelial 
Nasopharyngeal epithelium 
Epithelium cells 
Proteoglycan receptors 
Cell surface associated proteins 
CD46 
(Kallstrom et al., 1997a; De 
Vries et al., 1998; Melican and 
Dumenil, 2011). 
 
Staphylococcus aureus Fibronectin Skin tissue 
fibroblast 
Fibrinogen 
Heat shock protein (hsp60) 
(Cho et al., 2001; Schwarz-Linek 
et al., 2003). 
Streptococcus pygenes Sortase A Epithelial Fibronectin in the ECM (Beachey, 1981; Pancholi, 1989). 
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1.4 Strategies in anti-adhesion therapy 
It is increasingly evident that in addition to other defensive strategies, many bacteria form 
biofilms to resist unfavourable conditions such as antibiotic treatment and as such, there 
is need to employ other strategies for treatment of bacterial infections. Anti-adhesion 
therapy is a useful tool that can target the host or pathogen cell surface to disrupt bacterial 
cell attachment (the vital step of infection) in various ways (Figure 1.4).  
1.4.1 Anti-adhesive agents 
The development of new biological agents has allowed the treatment of several otherwise 
difficult to treat infectious diseases. For instance, probiotics have been widely used in 
anti-adhesion therapy for inflammatory diseases of the gastro-intestinal tract such as 
inflammatory bowel disease and ulcerative colitis mainly because of their (probiotic) 
presence in the intestinal flora (Guandalini, 2010). Probiotics are non-pathogenic bacteria 
that possess health benefits for hosts which they colonise. Several studies have shown 
that probiotics are effective against enteric pathogens through several mechanisms 
including production of bacteriocins by Lactobacilli with activity against Gram-positive 
bacteria (Cotter et al., 2005; Lawton et al., 2007), while bacteriocin produced by 
Bifidobacteria is active against Gram-positive and Gram-negative bacteria (Collado et 
al., 2005). Lactobacillus species have been demonstrated in previous studies to adhere to 
intestinal epithelial surfaces in tissue culture (Greene and Klaenhammer, 1994). L. 
acidophilus and L. rhamnosus were also shown in another study to adhere to host 
epithelial cells, thus preventing the binding of E. coli E2348/69 and E. coli O157:H7 to 
the host epithelial cells (Sherman et al., 2005). 
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In many systems, adhesion of the bacteria to host cells is mediated by the interaction 
between lectins on the bacteria and carbohydrates present on the host cell surface. Several 
studies have demonstrated the effective role of employing glycomimetics or sugar based 
inhibitors as anti-adhesives (Mulvey et al., 2001; Sharon, 2006). For instance, intestinal 
epithelium secretes mucus containing highly glycosylated mucin molecules, which act as 
a physical barrier against enteropathogens, thus preventing the pathogen from making 
contact with human intestinal epithelial cells. P. aeruginosa has a lectin (PA-IL), a 
carbohydrate binding protein, which forms dimers or tetramers that can bind sugars 
through an ion bridge formed with calcium at their binding sites (Cioci et al., 2003). The 
major role of these lectins is that they serve as ligands for pattern recognition receptors 
that are found on host cells involved in the innate immune system. The lectins expressed 
by P. aeruginosa, LecA and LecB, are produced by the Rhl system and play an important 
role in infection by binding to fucose or galactose as discovered in the mutagenesis studies 
by Winzer et al., (2000).  
High affinity glycomimetics such as analogues of Lewis trisaccharide and multivalent 
glycoconjugates like galactosylated helical poly (phenylacetylene) polymers, fullerenes, 
and calix (4) arenes have been developed. These have been shown to inhibit the binding 
of lectins to sugars, thereby preventing biofilm formation as observed with the 
fucosylpeptide dendrimers (Bernardi et al., 2013). Some bacteria possess structures that 
aid their binding to glycosylated surfaces and these glycomimetics act to prevent or 
destroy the binding of bacterial structures to the glycosylated surfaces. For instance, in 
UPEC, the type 1 fimbriae (pili) binds glycosylated surfaces in the urinary tract and 
glycomimetics such as heptyl α-D-mannopyranosides have been shown to prevent 
biofilm formation, cell adhesion and invasion of UPECs into bladder cells by acting as a 
structural mimic of the natural surface structure that UPECs bind to (Wellens et al., 2008).  
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1.4.1.1 Tetaspanins as anti-adhesive molecules 
Tetraspanins are expressed in virtually all cells and they mediate cell adhesion via 
interaction with adhesion molecules like E-cadherin and integrins (Yanez-Mo et al., 
2001). Until recently, the only study that investigated the role of tetraspanins in 
preventing bacterial adhesion to host cells was done by (Green et al., 2011a), where they 
assessed the effect of structurally modified tetraspanin molecules (recombinant 
tetraspanin) on the interaction between pathogens and host cells (monocyte-derived 
macrophages, and epithelial or endothelial cells). Green et al., (2011a) investigated the 
role of tetraspanins in cell-cell adherence and in the ability of pathogens to interact and 
adhere to the host cells. Epithelial cells (HEC1B and DETROIT 562 cells) were either 
incubated with specific anti-tetraspanin antibodies or with recombinant tetraspanin 
extracellular domains (EC2s) or both, which inhibited the attachment of N. meningitidis, 
E. coli, S. aureus and S. pneumoniae to epithelial cells. Small interfering RNA (siRNA) 
knockdown of the tetraspanins also gave similar result by inhibiting the adherence of N. 
meningitidis to the epithelial cells. These findings provide a link between tetraspanins and 
the pathogen interaction with epithelial cells, and thus gives insight into the use of 
recombinant tetraspanin proteins as anti-adhesives in preventing attachment of pathogens 
to host cells. The major advantage of this technique is that the recombinant tetraspanin 
can be made from human proteins and they are relatively small, therefore they will not 
elicit an immune response. Another benefit of this technique will be the ease of clearance 
of the protein as it is a biological agent.  
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Figure 1.4 Strategies in anti-adhesion therapy. 
The use of natural flora of the body to decrease the infection works by inhibiting the contact 
between the pathogen and the host. The normal flora can colonise specific niche and block the 
attachment of the pathogen to host cells. Adapted from Krachler and Orth, 2013. 
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1.5 Different methods used to investigate adhesion of bacteria to host 
cells 
The first step in infection is adhesion of the pathogen to host cells. Many anti-adhesion 
agents that block bacterial adhesion have been identified, including probiotics, which are 
capable of blocking the adhesion of pathogenic bacteria to host cell. Therefore, it is 
important to develop techniques that can detect or measure bacterial adhesion. Currently, 
there are various techniques available to detect or measure bacterial adhesion. However, 
these techniques are not well established and there are few studies that have compared 
these techniques to each other. Table 1.4 presents the comparison between different 
methods commonly used to quantify adhesion of bacteria to cells. 
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Table 1.4 Methods commonly used to quantify adhesion of bacteria to cells. 
Method Advantage Disadvantage References 
Plating (CFU) • Counts only the viable bacteria 
 
• The bacteria should be dissociated 
• Cannot discriminate bacteria in a mixed 
population 
• Not well suited for high throughput screening 
(HTS) 
• Counting of bacterial colonies may not be 
accurate 
• Laborious 
(Pederson and Breed, 1940; 
Vesterlund et al., 2005;  
Esteban Florez et al., 2016). 
Light Microscopy 
 
 
 
 
 
 
• It can determine the pattern of 
bacteria bound to individual cells 
• Allows direct measurement of 
bacteria bound to the specific 
cellular site 
• This method cannot be used when studying 
the adhesion of one bacterial strain 
• Time consuming 
• Cannot discriminate bacteria in a mixed 
population 
• Long process with fixation and staining 
(Garrett et al., 2008). 
Spectrophotometry • Does not require long lab process 
 
• Sensitivity and accuracy may be lower 
compared to plating or microscopic 
enumeration 
• Cannot distinguish bacteria in a mixed 
population 
• Does not differentiate between live and dead 
bacteria 
(Que et al., 2012).  
Electron 
Microscopy 
• Effective for quantitating bacteria 
bound to structures such as tissues 
• Expensive. 
• Sample preparation is complicated, the 
specimen requires to be coated with a very 
(Garrett et al., 2008). 
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thin layer of metal. 
Radiolabels • Distinguishes bacteria in a mixed 
population 
• Sensitive to detect small number of 
bacteria 
• Easy to obtain radiolabelled bacteria 
• Possible to monitor the simultaneous 
adhesion of bacteria to the same 
substrata 
• Safety and cost concerns (McEldowney and Fletcher, 
1987). 
Bioluminescence 
assays 
• Bioluminescence assays have 10–
1000× higher sensitivity levels than 
do fluorescence assays like green 
fluorescent protein/GFP 
• Provides a quantitative method for 
the assessment of bacterial viability 
• Allows exact quantification of 
the viability of cells within complex 
biological systems, such as 
oral biofilms 
• Difficult to exclude the background auto 
luminescence 
(Ray, 2008). 
Fluorescence (flow 
cytometry, image 
analysis) 
• Allows examination of bacterial 
adhesion to immobilised cells 
• Allows to study invasion of bacteria 
into cells 
• Specific population of cells can be 
separated by size 
• They may alter the surface properties of 
bacteria or affect the viability of bacteria 
 
(Esteban Florez et al., 
2016). 
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1.6 Application of flow cytometry in bacterial studies 
Flow cytometry is a powerful tool which can be used to investigate bacterial adhesion, 
which is critical for the pathogenesis of extracellular pathogens. Typically, bacterial 
invasion of eukaryotic cells is quantified by antibiotic assays followed by dilution plating 
and counting of colonies, which is time consuming and laborious. This antibiotic assay is 
based on the recovery of viable bacterial cells after its internalisation by eukaryotic cells, 
therefore “it can severely underestimate the number of intracellular bacteria if 
intracellular killing by eukaryotic cell occurs” (Pils et al., 2006a).  
Flow cytometry is a potential method for investigating the adherence of bacteria to host 
cells. Hytönen et al., (2006b) studied the adhesion of streptococcal strains and PulA 
deficient mutants to Squamous cell carcinoma (SCC) cells by both the conventional solid 
phase adhesion assays and flow cytometry, they found that with the conventional solid 
phase adhesion methods there was no difference in the binding of bacteria to host cells, 
while with the flow cytometric assay they found there was a statistically significant 
difference between the adhesion of streptococcal strains to the human epithelial cells. 
Consequently, there has been a rapid rise in the use of the flow cytometry technique for 
analysing host-pathogen interactions, specifically to measure the adhesion of bacteria to 
host cells. Previous studies have used flow cytometry to investigate the interaction 
between bacteria and eukaryotic cells, as well as fungi and other eukaryotic cells (Brooks 
et al., 2013). However, its potential application for complex studies has been 
underestimated. Lately, a flow cytometry-based approach was developed to analyse the 
adhesion of different strains of Trichomans vaginalis to vaginal ectocervical cells (Brooks 
et al., 2013). A limitation of the approach in this study was the inability to quantify 
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adhesion, but, other researchers have described that flow cytometry can be used to detect 
and measure viable microbes (Pina-Vaz et al., 2004; Barbosa et al., 2008; Pina-Vaz and 
Rodrigues, 2010). Previously, flow cytometry has been used to study the adhesion and 
invasion of S. aureus strain 8325-4 and its invasion-deficient isogenic mutant into 
osteoblastic MG-63 cells (Trouillet et al., 2011a). In order to be analysed by flow 
cytometry, bacteria need to be genetically modified to express fluorescent proteins, 
eukaryotic cells, on the other hand, are identified using the light scattering phenomenon. 
However, a direct labelling method has been developed to enable improved identification 
of the target cells (Hara-Kaonga and Pistole, 2007). 
Pils et al., (2006a) have previously developed a protocol, which verified the use of flow 
cytometry as a tool for defining the uptake of bacterial pathogens by host cell types such 
as epithelial cells or fibroblasts. However, in a mixed population of bacterial strains, flow 
cytometry was found to be unable to detect and accurately quantify the different strains 
using fluorescein-conjugated antibacterial antibody (Phillips and Martin, 1988). 
1.6.1 Basic principles of flow cytometry  
Flow cytometry is an advanced method used to measure multiple characteristics of a 
single cell. This technique enables the simultaneous measurement of multiple parameters 
such as size, granularity and volume as cells flow in suspension through a measuring 
device (Wilkerson, 2012). The cell suspension is mixed with the sheath fluid, the sheath 
fluid focuses the cell suspension, which makes cells pass in a single file towards a laser 
light source. The light source provides the fluorescence excitation, which strikes the 
moving particle passing through, leading to light scattering and fluorescence emission. 
The emission and light scattering are captured by a detector, which converts the 
information to data that can be processed and analysed.  
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Therefore, the data obtained gives valuable information about the biophysical, 
biochemical and molecular properties of particles and this approach makes flow 
cytometry a powerful tool for detailed and rapid analysis of a complex population of cells 
(Stuchly et al., 2012). Flow cytometry is used in numerous applications including 
cytokine detection, cell proliferation, cellular components and enzyme activity detection 
(Wlodkowic et al., 2013). 
1.6.2 Fluorochromes and their properties 
There are a restricted number of fluorescent compounds that can be used in a cell, which 
reduces the amount of information that can be obtained during analysis. Flexibility is 
achieved with the use of fluorochromes/fluoroprobes, which are fluorescent compounds 
attached to antibodies that re-emit light upon excitation and can be used to target specific 
proteins within the cell and on the surface (Davies, 2009). Fluorescent proteins such as 
GFP (green) and DsRed (red) were widely used as an indicator to observe gene expression 
by cell transformation. The fluorescent-labelled bacteria can be detected by flow 
cytometry, this provides an important tool to investigate bacterial pathogenicity (Valdivia 
et al., 1996).  
1.6.3 Data analysis 
Analysis of the flow cytometry data is critical to understanding the biological 
experiments. In flow cytometry, gating is used to selectively group together a population 
of cells with common characteristics, this allows the researcher to further investigate and 
quantify the selected cells with the aim of selectively showing the details of the cells of 
interest. This is achieved using characteristics such as forward and side scatter (FSC, 
SSC) of the cells to form regions. Careful selection for gating also provides the difference 
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between the particles and can easily eliminate dead cells and debris. FSC and SSC plots 
are used to separate cells by their characteristics such as size and shape in a mixed 
population. For example, the difference in size between white blood cells, granulocytes, 
lymphocytes and monocytes allows them to be separated from each other (Jahan-Tigh et 
al., 2012). 
1.7 Hypothesis and aim of the project 
In this study, it was hypothesised that disruption of TEM, by antibodies, recombinant 
tetraspanin EC2 domains or synthetic peptides (CD9 EC-derived peptides) will inhibit 
the attachment of P. aeruginosa to host cells and thus prevent infection. The aim of this 
study was to investigate whether tetraspanins play a role in the adhesion of P. aeruginosa 
to human epithelial cells and subsequently, to investigate the potential of using 
tetraspanin reagents as anti-adhesives in treating P. aeruginosa infections by inhibiting 
adherence to human epithelial cells if the tetraspanins are involved in adhesion. 
In order to investigate the role of tetraspanins in the pathogenic adhesion of P. aeruginosa 
to host cells, this project involved the following processes; 
i. Growth optimisation of P. aeruginosa followed by expression profiling of 
tetraspanins in human epithelial cells using flow cytometry. This involved the 
development of a fluorescent labelled bacteria for detecting the role of 
tetraspanins during the bacterial adhesion. 
ii. Developing flow cytometry based assay (which could potentially replace the 
microscopy assay) for investigating the role of tetraspanin reagents in bacterial 
adhesion. 
iii. The use of tetraspanin antibodies to investigate the inhibition of P. aeruginosa 
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adhesion to cells. 
iv. The use of recombinant tetraspanin molecules to inhibit P. aeruginosa adhesion 
to host cells, to investigate which tetraspanins are involved in adhesion to host 
cells. 
v. The use of tetraspanin CD9 derived peptides to inhibit P. aeruginosa adhesion to 
epithelial cells. 
vi. The use of tetraspanin CD9 derived peptide 810 to investigate the production of 
cytokines in epithelial cells. 
 
 
 
 
Figure 1.5 Disruption of TEM. 
The treatment of host cell with recombinant EC2 proteins, antibodies, or CD9 EC2-derived 
peptides may disrupt TEMs. This can cause the redistribution of host cell receptors and therefore 
prevent the bacteria from adhering to the host cell surface. (A) Normal organisation of TEM and 
bacterial receptors on the host cell surface (without tetraspanin treatments). (B) After tetraspanin 
treatments, receptors are redistributed and the pathogens can no longer adhere to the host cells 
and are removed by shear pressure.  
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CHAPTER 2: Materials and methods 
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2.1 Materials 
2.1.1 Reagents 
Table 2.1 Reagents used in this study. 
Reagents Preparation 
Dimethyl sulphoxide (DMSO) 
 
DMSO (Sigma) was used for freezing cells by 
diluting 10 x in cell culture media (containing 
10 % foetal calf serum). 
Gentamicin Gentamicin (Lonza) was used by diluting 0.8 
mg/ml from a 10 mg/ml stock in cell culture 
media. 
Saponin 
 
Saponin (Sigma) was prepared in 0.05 % 
trypsin-PBS at a concentration of 1 % and 
filtered before use. 
Trypsin-versene Trypsin- versene® (Lonza) was produced by 
the addition of 100 ml of 10 x trypsin-
versene® (EDTA) to 1 litre of Hank’s 
balanced salt solution (HBSS). Aliquots of 10 
ml were stored at -20 C for later use. 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma-
Aldrich, USA) was used according to the 
manufacturer’s instructions at a concentration 
of 0.5 mg/ml and stored at -20 °C until use. 
2.1.2 Solutions 
Table 2.2 Solutions used in this study. 
Solutions Preparation 
Cell dissociation solution 
 
Cell dissociation solution was purchased 
(CDS) (Sigma) as 1x solution. To dissociate 
the cells, 5 ml was added to a T75 Flask. 
Hanks buffered saline solution (HBSS) HBSS with/without Ca2+
 
and Mg2+
 
(Lonza). 
Paraformaldehyde solution 4 % 
 
4 g paraformaldehyde was dissolved in 50 ml 
of double distilled water (ddH2O) containing 
1 ml of 1 M solution of NaOH by heating for 
60 minutes at 60 °C. After cooling, 10 ml of 
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10 x PBS was added and the pH was adjusted 
to 7.4. The solution was diluted to 1 x with 100 
ml ddH2O, filter sterilised and stored at -20 
°C. 
 
2.1.3 Buffers 
Table 2.3 Buffers used in this study. 
Buffers 
 
Preparation 
Phosphate buffered saline (PBS), pH 7.3 
 
PBS containing NaCl (140 mM), Na2HPO4 (8 
mM), KCl (2.7 mM) and K2H2PO4 (1.5 mM) 
was prepared by dissolving 10 x phosphate 
buffered saline (PBS), 80 g NaCl, 2 g KCl, 
11.5 g Na2HPO4, 2 g KH2PO4 in 1 litre of 
H2O.  Aliquots were autoclaved for 15 
minutes at 121 °C. 
Triton X-100 (Lysis buffer) 
 
Triton X-100 (Sigma) was prepared in PBS at 
0.1 %. The solution was filter sterilised before 
use. 
Wash buffer/dilution buffer for 
immunofluorescence (BBN) 
 
BBN consisting of 0.1 % sodium azide and 
0.2 % bovine serum albumin (BSA) dissolved 
in PBS. BBN was stored at 4 °C. This was 
also used as a diluent for antibodies. 
2.1.4 Commercial kits used 
CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega) was purchased and used 
in accordance with the manufacturer’s instructions. 
2.1.5 Stains  
Table 2.4 Stains used in this study. 
Stains Preparation 
DAPI staining solution     
 
Staining solution was prepared by mixing 0.1 
% Triton X-100, 0.02 % sodium dodecyl 
sulphate and 0.5 μg /ml of 4, 6-diamidino-2- 
phenyl-indole hydrochloride (DAPI) in PBS. 
The solution was stored at 4-8 °C. 
Vectashield mounting medium 
 
Vectashield mounting medium (Vector 
Laboratories Inc., USA). The ready-to-use 
mounting medium was stored at 4 ºC. 
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2.1.6 Antibodies 
2.1.6.1 Primary antibodies 
Table 2.5 Primary antibodies used. 
 
 
2.1.6.2 Secondary antibody 
 Anti-Mouse IgG-FITC, FITC conjugates produced in goat (Sigma), Cat number F-
2653.  
2.1.7 Tetraspanin EC2 : GST protein  
The transformation was done using a modified protocol from Higginbottom et al., (2003) 
using two bacterial expression strains: E. coli Rosetta-gami B (DE3) pLysS (Novagen) 
and E. coli Shuffle T7 Express lysY (New England Biolabs) by co-workers Dr Marzieh 
Faneaei and Dr John Palmer. 
2.1.8 Tetraspanin derived peptides 
Solid phase synthesis with Fmoc chemistry (Houghten, 1985) was used to synthesise the 
EC2 region of tetraspanin CD9 (Tetraspanin 29), the majority of the peptides synthesised 
Antibody Target 
antigen 
Specificity Concentration 
used 
Source 
Mouse anti- human CD9 
(602.29) 
CD9 Human 10 μg/ml In house 
Mouse anti human 
(H5C6) 
CD63 Human 10 μg/ml In house 
Mouse anti human 
CD81 
CD81 Human 10 μg/ml Ancell 
product 
number:302-820 
Mouse anti- human 
CD151 (14.A2) 
CD151 Human 10 μg/ml In house 
Isotype-mouse IgG 1  Human 10 μg/ml BioLegend 
Cat:400124 
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were 14-15 amino acids long. They were purchased from GenScript in lyophilised form. 
They were prepared to the desired stock solution using ddH2O.  
Table 2.6 CD9 EC2 domain: peptide sequences. 
 
Peptide Description Amino acids sequence 
800 15 amino acids long, second central 
part of the large loop of EC2. 
EPQRETLKAIHYALN 
800 
(Scrambled) 
Scrambled control consisting of 15 
amino acids, second central part of 
the large loop of EC2. 
AYPHLERNLQEIAKT 
810 14 amino acids long, part of the 
second variable sub-loop of EC2. 
GPKKDVLETFTVKS 
810 
(Scrambled) 
Scrambled control consisting of 14 
amino acids, part of the second 
variable sub-loop of EC2. 
TSKEKLVGPDTKVF 
8001 14 amino acids long, stalk part of the 
large loop of EC2. 
SHKDEVIKEVQEFY 
8001 
(Scrambled) 
Scrambled control consisting of 14 
amino acids, stalk part of the large 
loop of EC2. 
EEVKKFESQHDIYV 
8002 13 amino acids long, first central part 
of the large loop of EC2. 
KDTYNKLKTKDEP 
8002 
(Scrambled) 
Scrambled control consisting of 13 
amino acids, first central part of the 
large loop of EC2. 
NEKDPKKTLDKTY 
8003 14 amino acids long, part of the first 
variable sub-loop of EC2. 
GLAGGVGQFISDIS 
8003 
(Scrambled) 
Scrambled control consisting of 14 
amino acids, part of the first variable 
sub-loop of EC2. 
IDSGFVGQIASGLE 
8004 11 amino acids long, latter stalk part 
of the large loop of EC2. 
PDAIKEVFDNK 
8004 
(Scrambled) 
Scrambled control consisting of 11 
amino acids, latter stalk part of the 
large loop of EC2. 
AFPDNKDIVEK 
8005 Extended peptide 8001 to include 
entire helix 
SHKDEVIKEVQEFYKDTYNKLKT
KDEPQRETLKAIHYALN 
8005 
(Scrambled) 
Scrambled control for extended 
peptide 8001 
THDAEKKNPINDLKKEVLERVK
QKTYESTHFADLYQIEYK 
800 Cap Peptide 800 capped with Asp (D) DEPQRETLKAIHYALN 
800 Cap 
(Scrambled) 
Scrambled control for peptide 800 
capped with Asp (D) 
QEALKYNRAETPLDIH 
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2.1.9 Bacteriology work 
2.1.9.1 Media 
Table 2.7 Bacteriology media. 
Media Preparation 
LB (Lysogeny Broth) 
 
10 g tryptone, 5 g yeast extract and 10 g 
sodium chloride were added to 1 litre 
distilled water and autoclaved at 121 °C. 
LB agar 
 
10 g tryptone, 5 g yeast extract, 10 g sodium 
chloride and 15 g agar were added to 1 litre 
distilled water and autoclaved at 121 °C. 
 
2.1.9.2 Antibiotics 
Chloramphenicol 
100 μg of chloramphenicol was dissolved in 2 ml ethanol (Fisher Scientific) and stored 
at -20 °C. 
2.1.9.3 Glycerol stock 
Glycerol was purchased (Sigma), 700 µl of overnight bacterial culture was added to 300 
µl of glycerol and kept in -80 °C freezer until required. 
2.1.9.4 Plasmids encoding fluorescent proteins  
The PIN25 (GFP) plasmid and PIN29 (DsRed) plasmid were obtained from Dr Mark 
Thomas (Department of Infection, Immunity and Cardiovascular Disease, Medical 
School, University of Sheffield) (Vergunst et al., 2010). 
2.1.9.5 Bacterial strains used in this study 
• (PAO1) Wild type Pseudomonas aeruginosa; wound isolate (Holloway, 1955). 
• (SH1000) Staphylococcus aureus is derived from RN4220 and contains a 
chloramphenicol resistance pSK5487 plasmid expressing GFP (Herbert et al., 
2010). 
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PAO1 and SH1000 were grown in LB broth media containing 50 µg/ml and 10 µg/ml of 
chloramphenicol, respectively. Bacteria were maintained on LB agar plates at 4 °C (for 
short-term storage) and in 15 % glycerol-LB broth at -80 °C (for long-term storage). 
2.1.10 Cell line culture and media used 
2.1.10.1 Media and sera 
Dulbecco’s modified essential medium (DMEM) 
For infection assays, DMEM-high glucose (Lonza) was made by adding 50 ml FCS and 
250 μl chloramphenicol (50 μg/ml for PAO1 and 10 μg/ml for SH1000), and stored at 5 
°C. 
Eagle’s modified essential medium (EMEM) 
For infection assays, EMEM + 1 % L-glutamine (Lonza) was made by adding 50 ml FCS 
and 250 μl chloramphenicol (50 μg/ml), and stored at 5 °C. 
Foetal calf serum (FCS) 
Foetal calf serum was purchased (Source Bioscience, UK). It was further heat inactivated 
(HI-FCS) by incubation at 56 °C for 20 minutes, and then frozen in 50 ml aliquots until 
use.  
Bovine serum albumin 
 
Bovine serum albumin (First Link Ltd., UK) at 30 % was diluted in cell culture media 
to a concentration of 0.05 %.  
2.1.10.2 Cell lines  
Adenocarcinoma human alveolar basal epithelial cells (A549) (Lieber et al., 1976), 
human keratinocytes (HaCaT) (Boukamp et al., 1988), and human endometrial 
adenocarcinoma epithelial cells (HEC1B) (Kuramoto et al., 1972), were used throughout 
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this study. These cell lines were kindly provided by Dr Lynda Partridge (University of 
Sheffield) from the in-house culture collection cell bank.  
2.2 Methods 
2.2.1 Tissue culture methods 
2.2.1.1 General sub-culture technique 
At confluence, culture media from the cells was carefully decanted using aspiration and 
the cells were gently rinsed with sterile PBS solution twice. After decanting the PBS 
solution by aspiration, cells were detached from the flask using the appropriate reagents 
depending on the cell type and incubated at 37 °C with 5 % CO2 in a humidified incubator 
for about 5 minutes. The cells were removed from the incubator and slightly agitated by 
gently shaking the flask to completely detach the cells. The cells were re-suspended in 
appropriate amount of culture medium and the number of viable cells was counted using 
a haemocytometer prior to sub-culturing. The cells were then diluted with culture media 
depending on cell growth rate into new flasks and incubated at 37 °C with 5 % CO2. 
2.2.1.2  Cell freezing 
The cells were detached from the flask as described before in section 1.10.8, centrifuged 
at 200 xg for 5 minutes and re-suspended in 1 ml of the freezing mixture (10 % DMSO 
and 90 % FCS). The cells were initially frozen at -80 oC for 24 hours and then transferred 
to liquid nitrogen vapour for long-term storage. 
2.2.1.3 Cells thawing 
The cells were transferred to 9 ml of growth media without FCS and centrifuged for 5 
minutes. Then, the cell pellets were re-suspended into fresh media with FCS and 
transferred to a T25 flask, and allowed to grow at 37 °C with 5 % CO2 for 24 hours. 
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2.2.1.4 The live/dead fixable cell stain 
The live/dead fixable cell stain was supplied by Invitrogen. The stain was prepared by 
adding 100 μl DMSO to the vial of reactive dye, and then the dye was diluted in PBS to 
the required volume. Cells were centrifuged and the pellet re-suspended in 200 μl of the 
dye and incubated for 15 minutes at room temperature (in the dark). The purpose of this 
method was to evaluate the viability of human cells by flow cytometry. These tests are 
based on the reaction of a fluorescent dye with cellular amines. The reactive dye can only 
penetrate the compromised membranes of necrotic cells and react with free amines both 
in the interior and on the cell surface, resulting in intense fluorescent staining. In 
comparison, only the cell-surface amines of viable cells are accessible to react with the 
dye, causing in relatively dim staining (Figure 2.1). 
 
 
 
Figure 2.1 Flow cytometry analysis of cells stained with live/dead stain. 
(A) The gate for all cells (live + dead). (B) Live cells (left) and dead (right). Analysis was 
done using the Attune FACS machine. 
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2.2.1.5 Labelling of plasma membrane antigens (immunofluorescence assay in 
tubes) 
Immunofluorescence assays were performed on live cells and all cell manipulations were 
carried out at 4 °C to prevent internalisation, capping and shedding of antigens. For each 
test/assay, 0.5 to 1.0 x 106 cells of high viability (90 %) were used; the cells were 
harvested after culturing and washed twice in cold wash buffer (BSS containing 0.2 % 
BSA, 0.1 % sodium azide i.e. BBN). Total cells (0.5 to 1.0 x 106 cells) were re-suspended 
in the wash buffer and 1 ml aliquots were added to round bottom polystyrene tubes, 
(Elkay 12 × 75 mm, Cat. No. 000-2052-001) and centrifuged at 400 xg for 5 minutes. The 
supernatant was carefully aspirated using Pasteur pipette or micropipette and 50 µl of 
mouse polyclonal antibody (MAb), diluted in wash buffer as required, was added to the 
cell pellet. The tube was gently vortexed for few seconds and the content was incubated 
on ice for 45-60 minutes. The cells were washed as previously described and subjected 
to fluorescence-activated cell sorting (FACS) LSR II analysis. Primary antibodies were 
unlabelled while secondary antibodies were labelled. For FACS, the cells were re-
suspended with 0.3 ml of wash buffer and were kept on ice until analysis or fixed in 0.3 
ml of 2 % paraformaldehyde to be kept for up to 48 hours.  
2.2.1.6 Immunofluorescence on cells grown on LabTech chamber slides (indirect 
staining) 
Cells were harvested as described above (section 2.1.5) using trypsin/versene and the 
viable cells were counted. Cells were re-suspended in culture medium at approximately 
7 x 104 cells/ml and 0.5 ml aliquots of the re-suspended cells were added into a LabTech 
chamber slide and incubated overnight at 37 °C with 5 % CO2. The slides were examined 
the following day to check the cell density. The cells were washed again with 0.5 ml BSS 
by processing one slide at a time to avoid drying of the cells in chambers. The cells in 
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each chamber were fixed and permeabilised with 0.5 ml acetone and incubated at room 
temperature for 5 minutes. The acetone was removed from each chamber by aspiration 
and the chambers were gently rinsed by immersing the slides in PBS, and then flicked to 
remove the acetone. The slides were then placed in a tank containing fresh PBS and 
washed for 10 minutes with stirring. The slides were removed from the PBS tank, drained, 
and 100 µl of primary antibody was added to cover the entire surface of the slide and 
incubated for 30 minutes at RT in dark under humid conditions. The slides were rinsed 
with PBS for about 10 minutes, the third time and drained, followed by addition of 100 
µl of secondary antibody labelled with FITC as quickly as possible. Then the slides were 
incubated at RT in the dark under humid conditions for 30 minutes. Next, the slides were 
washed again as above and were removed from the chambers and mounted on a plastic 
chamber compartment according to manufacturer’s instructions as described above. The 
slides were stored in the dark at 4 °C until fluorescent microscopic analysis. 
2.2.2 Bacteriology methods 
2.2.2.1 Bacterial culture techniques  
Solid culture technique for viable bacteria 
 
Viable bacterial cells were stored at -80 °C in 50 % glycerol in LB media. When needed, 
aliquots of the bacterial stocks were streaked using a sterile metal loop and transferred 
onto solid LB agar containing chloramphenicol at 50 μg/ml. The plates were incubated in 
a humidified incubator at 37 °C to allow growth of individual colonies. Bacteria were 
propagated on fresh solid media on a daily basis and it was assumed that each individual 
colony developed from one viable bacterium. Several individual colonies were used to 
streak fresh solid agar plates so as to avoid phase variability of surface structures, 
especially with the use of the Pseudomonas genus.  
Broth culture technique for viable bacteria  
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LB with 50 μg/ml chloramphenicol was used for Pseudomonas: 8-12 individual colonies 
of Pseudomonas were picked from the overnight solid agar culture plate using a sterile 
loop and each colony was used to inoculate 10 ml of fresh LB broth in a 25 ml universal 
tube. The cultures were incubated with agitation (using a plate mixer) for 2 hours at 37 °C. 
The absorbance of the culture was measured at OD600nm and the number of viable bacteria 
were counted to ensure the approximate CFU/ml can be calculated for each dilution that 
would be required in the subsequent experiments. 
2.2.2.2 Bacterial growth curve 
To estimate the number of viable bacteria in culture, a tenfold serial dilution of the 
bacterial culture was made and each dilution was plated on LB agar. The agar plates were 
quartered to accommodate four dilutions per plate. Triplicates of 10 µl aliquots of the 
serial dilutions were inoculated on each quarter, thus avoiding coalescence. The plates 
were air dried in a class II microbiological safety cabinet prior to incubation in a 
humidified environment at 37 °C. For each dilution, using the triplicates, the mean 
bacterial count in CFU/ml (colony forming units) was calculated using the Equation 
(2.1), and the numbers were adjusted for volume and dilution.  
 
Equation (2.1)      Colony forming units /ml= 
number of colonies x 
1
volume plated (ml) 
x dilution factor 
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2.2.2.3 Labelling of Pseudomonas with fluorescent protein encoding plasmids 
(PIN25 & PIN29) 
P. aeruginosa strains were inoculated in 6 ml of LB broth. The cultures were left to 
incubate overnight at 37 °C whilst shaking. The overnight cultures were divided into four 
1.5 ml micro-centrifuge tubes. The tubes were centrifuged at 16,000 xg for 2 minutes at 
room temperature (RT) and the cells were harvested by decanting the broth. The pellet 
was gently re-suspended in 1 ml of sterile 300 mM sucrose solution using a micropipette. 
The re-suspended pellets were centrifuged at 16,000 xg for 1 minute and the supernatant 
was discarded. This step was repeated with the centrifugation step completed for 2 
minutes. Cell pellets from the four samples were re-suspended to make a total volume of 
100 µl with 300 mM sucrose solution by sequentially re-suspending each pellet in the 
same 100 µl volume. 500 ng of vector DNA was mixed with 100 µl of P. aeruginosa 
bacterial cells and transferred into a 2 mm-gap width electroporation cuvette. Pulse was 
applied using the automated settings for the bacteria P. aeruginosa in the Bio-Rad gene 
pulser (25 µF, 200 Ω, 2.5 kV). Afterwards, the electroporated cuvette was opened in a 
microbiological safety cabinet and 1 ml of LB broth was added to the content. The culture 
was then transferred into a sterile universal tube and incubated at 37 °C for 2 hours whilst 
shaking. The cells were plated onto selection plates after incubation. The selection marker 
was chloramphenicol, which was used at 50 µg/ml. 
2.2.3 Preparing fluorescent labelled- P. aeruginosa for infection assays 
Fluorescent labelled- P. aeruginosa were prepared before each experiment by streaking 
onto LB agar from bacterial stock to isolate single colonies. Overnight liquid cultures 
were then prepared by inoculating one bacterial colony into 10 ml LB broth with 50 µg/ml 
chloramphenicol, the bacteria were allowed to grow in a shaking incubator (120 rpm) for 
16-18 hours at 37 °C.  After incubation, the overnight culture was centrifuged for 10 
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minutes at 4,500 xg. The bacterial pellet was washed with PBS twice and then suspended 
in 5 ml of appropriate cell culture media according to cell line used in the experiment. 
The OD600 was determined to be diluted to OD600 of 0.5, CFU/ml of 5x108.   
2.2.4 Microscopic detection of fluorescent labelled -P. aeruginosa adherence 
to the host cell 
2.2.4.1 Adhesion assay 
Cells were seeded in a 24 well plate at a density of 1.5 x 105 cells/ml on 12 mm coverslips 
and allowed to grow overnight at 37 oC with 5 % CO2. The next day, the medium was 
removed and wells washed once with PBS using a Pasteur pipette. Cells were then 
infected with the bacteria at a range of MOIs (5, 10, 15, 20, 25, 30, 35 and 40) and 
incubated at 37 oC with 5 % CO2 for 60 minutes. Cells were then washed twice with PBS. 
2.2.4.2 Staining protocol for infected cells 
2 % paraformaldehyde was used to fix the infected cells for no less than 30 minutes. Once 
the paraformaldehyde was removed, the cells were washed twice with PBS, then 400 µl 
solution of PBS containing 0.1 % Triton X-100, 0.02 % sodium dodecyl sulphate and 0.5 
μg ml-1 DAPI was added to each well and left in the dark at room temperature for 12 
minutes. A single drop of DAPI hard mounting media was placed on the slide before the 
coverslip was placed with cells facing DAPI. Later, cellular DNA was visualised using 
the UV wavelength light on a fluorescent microscope at a maximum excitation 
wavelength of 368 nm and a maximum emission wavelength of 461 nm. 
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2.2.4.3 Analysis of infected cell slides 
An Olympus fluorescence microscope (BX61) at 1000 x magnification (oil-immersion 
lens) was used in a random field to count 100 cells, with bacterial adhesion calculated as 
shown in Equations (2.2a-c).  
 
Equations (2.2) 
a). Percentage infected= 
Infected cells
Number of cells
 x100 
b). Number of bacteria per 100 cells= 100x 
Number of bacteria
Number of cells
 
c). Bacteria per infected cells= 
Number of bacteria 
Number of infected cells
 
 
2.2.5 Flow cytometric detection of fluorescent labelled -P. aeruginosa 
adherence to the host cell 
The cells were washed as described above (section 2.2.3) and seeded into a 96-well plate 
at 1.0 x 105 cells/well in 100 µl of growth medium. Additional cells were retained for 
gating of the flow cytometer. The 96-well plate was centrifuged at 400 xg for 5 minutes 
and the media in the plate was aspirated. The cells were re-suspended in PBS by pipetting 
up and down. Next, the cells were centrifuged as before and the PBS aspirated. 100 µl of 
bacteria in media was added to the cells at a range of MOIs and incubated at 37 oC for 60 
minutes. Then, the plate was centrifuged at 400 xg for 5 minutes, the media was aspirated, 
and the cells were rinsed with PBS as before. The PBS was aspirated and the cells were 
fixed in paraformaldehyde for 30 minutes at 4 °C. Prior to FACS analysis, the cells were 
re-suspended gently by pipetting up and down for a few times. Attune FACS machine 
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was used (488 nm Laser, 530/30 BL1) at the flow cytometry core service at the Medical 
School, The University of Sheffield.  
2.2.6 Effect of tetraspanin reagents on GFP labelled -P. aeruginosa adherence 
to the host cell 
The cells were seeded as described above. Cells were incubated in presence or absence 
of anti-tetraspanin antibodies  isotype control at 10 l/ml, or EC2: GST proteins / GST 
control at 500 nM, or CD9-derived peptides at 20 nM for 30 minutes. Cells were then 
washed with PBS and infected as described (section 2.2.4 or 2.2.5). 
2.2.7 Cytokine measurements 
Cells were seeded at 1 x 105 cells/well (1 ml volume) in a 24-well plate and incubated at 
37 °C with 5 % CO2 for 24 hours. An overnight culture of P. aeruginosa was prepared at 
37 °C. The overnight culture was centrifuged at 4,500 xg for 10 minutes at 4 °C, and 
diluted to OD600 of 0.5 in DMEM (+ 1 % FBS + 50 µg/ml chloramphenicol). Cells were 
washed twice by pipetting with PBS and 250 µl of bacterial suspension was added at MOI 
of 35 and incubated at 37 °C with 5 % CO2 for 60 minutes. After incubation, cells were 
gently washed with 1 ml of PBS (2 x) to remove any non-adherent bacteria. After 
washing, 250 µl of DMEM containing 250 µg/ml gentamicin and 1 % FBS was added, 
gentamicin was added to prevent further growth of extracellular bacteria. Cells were 
incubated for three-time points (60 minutes, 6 hours and 18 hours). After incubation, the 
supernatants were collected at each time point and centrifuged at 16,000 xg to pellet the 
bacteria, and the clear supernatant was transferred to fresh tubes and stored at -80 °C until 
analysis by Cytometric Bead Arrays (CBA). CBAs were run by the flow cytometry core 
facility at the Medical School, the University of Sheffield according to the protocol by 
BD Biosciences. In principle, beads are coated with antibodies against a particular 
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cytokine and added to the sample. The beads are then rinsed to remove any unspecific 
binding and a secondary fluorescent-tagged antibody is added to allow detection of the 
beads using flow cytometry. Samples were analysed for the following cytokines: IL-6 and 
IL-8. These cytokines were selected for investigation as they are released during the initial 
stages of infection (Sadikot et al., 2005). 
2.2.8 Assessment of cytotoxicity using lactate dehydrogenase release  
The following method was taken from (Issa, 2016).  The CytoTox 96® non-radioactive 
cytotoxicity assay (Promega, UK) was used to measure the level of lactate dehydrogenase 
(LDH) in the supernatant, an indicator of cytoplasmic membrane damage, LDH is 
released when the integrity of the membrane is compromised. 1 x 104 cells/well were 
seeded in a 96-well plate and incubated at 37 °C with 5 % CO2 for 24 hours to achieve a 
70-80 % confluent monolayer. Monolayers were infected with bacteria at MOI of 10 for 
60 minutes at the incubator. After incubation, the supernatants collected from the plate 
wells were transferred to a fresh 96-well plate at 50 μl/well. The supernatants were mixed 
with the CytoTox 96® substrate at a ratio of 1:1, and incubated at room temperature for 
30 minutes. The reaction was then terminated by the addition of 50 μl ‘stop’ solution 
(provided with the kit). Absorbance was measured at 490 nm using the Thermo Scientific 
Varioskan plate reader. Maximum LDH release was determined as the amount released 
by total lysis of uninfected cells with 1 % TritonI X-100 (Sigma Aldrich, UK). Percentage 
cytotoxicity was calculated using the Equation (2.3). 
 
Equation (2.3)        Percentage cytotoxicity = 
LDH release in treated cells 
Maximum LDH release
 x 100 
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2.2.9 GFP-labelled P. aeruginosa internalisation assay 
2.2.9.1 Determining the optimum multiplicity of infection (MOI) for internalisation 
assay 
The following method was taken from (Ali, 2016).  In order to investigate the ability of 
GFP-labelled P. aeruginosa to internalise into A549 cells, a modified protocol by 
Schaible et al., (2013) was used. A549 cells were seeded in a 6 well plate for 48 hours at 
37 °C with 5 % CO2. Adherent cells were washed twice with 2 ml of PBS before 
incubation with GFP-labelled P. aeruginosa at a range of MOIs (1, 10 and 50) at 37 °C 
with 5 % CO2 for 60 minutes to allow the bacteria to adhere to epithelial cells. Internalised 
bacteria were quantified by exposing A549 cells to gentamicin in order to kill the 
extracellular bacteria. The antibiotic was prepared in DMEM media at a concentration of 
800 μg/ml, and A549 cells were treated with 1 ml gentamicin for 60 minutes at 37 °C 
with 5 % CO2. After incubation with the antibiotic, cells were washed twice with 2 ml of 
PBS and treated with a lysis solution consisting of 1 % saponin (Sigma Aldrich, UK) in 
trypsin-versene (the sensitivity of GFP-labelled P. aeruginosa to gentamicin and the lysis 
solution was also examined). A 1 ml aliquot of saponin solution was added to each well 
and the A549 cells were incubated for 20 minutes at 37 °C with 5 % CO2, allowing 
permeabilisation of the A549 cells and recovery of internalised bacteria. 100 μl aliquots 
were then spread onto LB plates. Next, the agar plates were incubated at 37 °C with 5 % 
CO2 for 24 hours before the bacterial colonies were counted. Each assay contained two 
replicate wells. The assay was performed three times.  
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2.2.9.2 The effect of CD9 EC2-derived peptides on GFP-labelled P. aeruginosa 
internalisation  
A549 cells were seeded in a 6 well plate for 48 hours at 37 °C with 5 % CO2. Adherent 
cells were washed twice with 2 ml of PBS before incubation with the selected CD9 EC2-
derived peptides for 30 minutes at 200 nM, cells were then infected with the bacteria at 
MOI of 10 for 60 minutes to allow the bacteria to adhere to epithelial cells. Internalised 
bacteria were quantified as described in section 2.2.9.1.  
2.2.10 Assessment of peptides cytotoxicity  
2.2.10.1 Effect of peptides on bacterial viability (ATP assay) 
The following method was taken from (Issa, 2016).  Adenosine triphosphate (ATP) 
production was measured using the BacTiter-GloTM Assay (Promega, UK). Cultures of 
P. aeruginosa were exposed to peptides at 200 nM at the mid-exponential phase (OD600 
of ~0.5). At each time point, (0 hours, 2 hours and 24 hours) the bacterial culture was 
diluted 1:1000 in LB broth and an aliquot (50 μl) was transferred to a NuncTM white 
opaque 96-well plate (Thermo Scientific, UK). The diluted culture was then mixed with 
an equal volume of BacTiter- GloTM reagent. The mixture was shaken at 120 rpm for the 
time point (2 hours, 24 hours) and incubated at room temperature for 2 minutes. 
Luminescence, proportional to the amount of ATP present, was measured as relative light 
units (RLU) using the Thermo Scientific Varioskan. 
2.2.10.2  Effect of peptides on human cell viability (MTT assay)  
The following method was taken from (Issa, 2016).  The MTT (3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide) assay (Promega) was used to determine the 
toxicity of peptides at 500 nM concentration against the A549 cells. The assay depends 
on mitochondrial activity, which is represented by the change in the dye from yellow 
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tetrazolium MTT into intracellular purple formazan crystals by metabolically active cells 
(Berridge et al., 2005). 1 x 104 cells/well were seeded in a 96-well plate and incubated at 
37 °C with 5 % CO2 for 16 hours to achieve a 70-80 % confluent monolayer. Monolayers 
were incubated with tetraspanin derived peptides at 500 nM in media for 30 minutes. The 
peptides were then removed and the monolayers washed with PBS. Then, 100 μl of 0.5 
mg/ml tetrazolian MTT dye prepared in FBS free media was added. Cells were incubated 
at 37 °C with 5 % CO2 for 4 hours in the dark to allow the formation of formazan crystals. 
After incubation, media was removed and cells washed with PBS. Formazan crystals were 
liquefied in 100 μl DMSO at room temperature with gentle agitation for 60 minutes. 
Absorbance was measured at 540 nm with a reference measurement at 690 nm, using a 
Thermo Scientific Varioskan plate reader. Equation (2.4) was used to calculate the 
percentage viability  
 
 
Equation (2.4)        Percentage viability = 
the absorbance of treated cells
 absorbance of untreated cells
 ×  100 
 
2.2.11 Statistical analyses 
Microsoft Excel and ImageJ were used to analyse the data. Graph Pad Prism 7 was used 
for the statistical analysis. Statistical test chosen is specified in the appropriate figure 
legend. Data were analysed using One-way analysis of variance (ANOVA) unless 
otherwise specified. In all cases reported N numbers refer to separate experiments, and 
all experiments were done at least three times unless listed otherwise. 
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CHAPTER 3: Tetraspanin expression levels in 
different human cells
  59 
3.1 Introduction 
Tetraspanins are a superfamily of membrane proteins expressed in many eukaryotic cells, 
and in humans, 33 members have been recognised (Boucheix and Rubinstein, 2001). 
Tetraspanins associate with other tetraspanin members or cell membrane proteins or 
lipids to form tetraspanin enriched microdomains (TEM) (Hemler, 2003; Wright et al., 
2004). TEM have been shown to mediate many important functions, such as adhesion, 
fusion and invasion (Fanaei et al., 2011). In order to investigate the role of tetraspanins 
in bacterial adhesion, it was important to determine the expression level of each 
tetraspanin in all the cell lines used in this study. 
3.1.1 Tetraspanin distribution 
Tetraspanins mediate different functions in different cells and tissues, this is reflected by 
the varied distribution in different cells, with each cell having a spectrum of tetraspanins 
that participate in the generation of specific functional microdomains (TEMs) (Levy and 
Shoham, 2005b). The production and subsequent trafficking of tetraspanins to cellular 
and organellar membranes is a well-regulated process that safeguards proper function. 
Though some tetraspanins appear to be distributed in all cell types (e.g. CD151 and CD9), 
others are relatively cell-type specific, for example, the uroplakins, that are found 
primarily in the epithelium of the urinary bladder (Xie et al., 2006).  
 
The aim of this chapter: 
• To investigate the expression level of selected tetraspanins in the three cell lines 
used for bacterial adhesion studies. This knowledge will help to determine 
which tetraspanin reagents are likely to be effective. 
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3.2 Results  
Immunofluorescence microscopy and flow cytometry were used for screening, section 
2.2.1.5 and 2.2.1.6, the three cell lines used in this study included: A549, a human lung 
carcinoma epithelial cell line (Lieber, Smith et al., 1976), HaCaT, a human keratinocyte 
cell line (Boukamp, Petrussevska et al., 1988) and HEC1B, a human endometrial 
epithelial cell line (Kuramoto, Tamura et al., 1972). 
3.2.1 Microscopic visualisation of tetraspanin expression in A549 cells 
In order to determine the expression of tetraspanins (CD9, CD63, CD81 and CD151) in 
A549 cells, immunofluorescence microscopy was performed using indirect staining of 
the cell lines seeded on chamber slides, as described in section 2.2.1.6. Visualisation of 
the target tetraspanin expression in permeabilised A549 epithelial cells showed high 
expression of CD9, CD63, and CD81, compared to the control (isotype); however, the 
expression of CD151 was low in these cells. The images in Figure 3.1 are a demonstration 
of the levels of these tetraspanins in A549 cells.  
3.2.2 Flow cytometry analysis of tetraspanin expression in A549 cells 
The quantitative evaluation of tetraspanin cell surface expression in the A549 cell line 
was performed using the LSRII FACS machine, as described in section 2.2.1.5. The cell 
population was gated depending on the FSC and SSC parameters (Figure 3.1. A and B). 
Figure 3.1 C shows the median fluorescence intensity (MFI) of A549 epithelial cells, the 
result revealed high expression of CD9, CD63 and CD81, compared to the control 
(isotype), whilst the expression of CD151 was lower than the other tetraspanins. The 
immunofluorescence microscopy analysis of tetraspanin expression in A549 cells was 
consistent with the data obtained by flow cytometry.   
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Figure 3.1 Analysis of selected tetraspanin expression in A549 cells using 
immunofluorescence microscopy. 
A549 cells were cultured on chamber slides and fixed. Nuclei were counter-stained with DAPI. 
The primary monoclonal antibodies (mAbs); JC1 (isotype control), anti-CD9, anti-CD63, anti-
CD81 and anti-CD151 were used at 10 μg/ml, this was followed by incubation with FITC 
conjugated anti-mouse IgG. The images were obtained with an Olympus fluorescent microscope 
by using the 100 x objective, scale bar represents 7 μm.
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Figure 3.2 Analysis of selected tetraspanin expression in A549 cells using flow 
cytometry.  
The primary monoclonal antibodies (mAbs); JC1 (isotype control), anti-CD9, anti-CD63, anti-
CD81 and anti-CD151 were used at 10 μg/ml, this was followed by incubation with FITC 
conjugated anti-mouse IgG. (A) The dot plot shows A549 cells gated according to forward scatter 
(FSC) and side scatter (SSC). (B) The histogram plot shows tetraspanin expression levels 
compared to the isotype control. (C) Median fluorescent intensity (MFI), error bars describe the 
standard error, N= 4, mean ± SEM. Data were analysed by One-way ANOVA with Dennett’s 
multiple comparison test, ****P < 0.0001, ***P < 0.001. 
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3.2.3 Microscopic visualisation of tetraspanin expression in HaCaT cells 
Screening of tetraspanin expression on the HaCaT keratinocyte cells was performed as 
described above 3.2.1. The results revealed high expression of tetraspanins CD9 and 
CD63, while the expression of tetraspanin CD81 was lower but detectable. However, 
CD151 was poorly expressed in these cells, with staining similar to that of the isotype 
control (Figure 3.2). 
3.2.4 Flow cytometry analysis of tetraspanin expression in HaCaT cells 
Analysis by flow cytometry showed a different pattern of tetraspanin expression 
compared to immunofluorescent microscopy. High expression of CD81 was observed in 
terms of median fluorescent intensity with relatively low expression of CD9 and CD151 
and little expression of CD63, compared to the isotype control (Figure 3.4).  
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Figure 3.3 Analysis of selected tetraspanin expression in HaCaT cells using 
immunofluorescence microscopy. 
HaCaT cells were cultured on chamber slides and fixed. Nuclei were counter-stained with DAPI. 
The primary monoclonal antibodies (mAbs); JC1 (isotype control), anti-CD9, anti-CD63, anti-
CD81 and anti-CD151 were used at 10 μg/ml, this was followed by incubation with FITC 
conjugated anti-mouse IgG. The images were obtained with an Olympus fluorescent microscope 
by using the 100 x objective, scale bar represents 7 μm.
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Figure 3.4 Analysis of selected tetraspanin expression in HaCaT cells using flow 
cytometry.  
The primary monoclonal antibodies (mAbs); JC1 (isotype control), anti-CD9, anti-CD63, anti-
CD81 and anti-CD151 were used at 10 μg/ml, this was followed by incubation with FITC 
conjugated anti-mouse IgG. (A) The dot plot shows HaCaT cells gated according to forward 
scatter (FSC) and side scatter (SSC). (B) The histogram plot shows tetraspanin expression levels 
compared to the isotype control. (C) Median fluorescent intensity (MFI), error bars describe the 
standard error, N= 4, mean ± SEM. Data were analysed by One-way ANOVA with Dennett’s 
multiple comparison test, ****P < 0.0001, ***P < 0.001. 
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3.2.5 Microscopic visualisation of tetraspanin expression in HEC1B cells 
Microscopic visualisation of permeabilised HEC1B cells showed a high expression of 
CD9 on the plasma membrane compared to the isotype control. In contrast, low 
expression was detected for CD63 compared to the tetraspanin CD9. Besides, CD151 
displayed the smallest amount of fluorescence compared to the other tetraspanins (Figure 
3.5). 
3.2.6 Flow cytometry analysis of tetraspanin expression in HEC1B cells 
Flow cytometry analysis revealed a high expression level of CD9 in HEC1B cells, this 
would indicate that these cells are a reasonable model for studying tetraspanin function 
in a human epithelial cell. However, CD63 and CD151 were found to be expressed at 
very low levels (Figure 3.6).  
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Figure 3.5 Analysis of selected tetraspanin expression in HEC1B cells using 
immunofluorescence microscopy.  
HEC1B cells were cultured on chamber slides and fixed. Nuclei were counter-stained with DAPI. 
The primary monoclonal antibodies (mAbs); JC1 (isotype control), anti-CD9, anti-CD63, anti-
CD81 and anti-CD151 were used at 10 μg/ml, this was followed by incubation with FITC 
conjugated anti-mouse IgG. The images were obtained with an Olympus fluorescent microscope 
by using the 100 x objective, scale bar represents 7 μm. 
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Figure 3.6 Analysis of selected tetraspanin expression in HEC1B cells using flow 
cytometry.  
The primary monoclonal antibodies (mAbs); JC1 (isotype control), anti-CD9, anti-CD63, anti-
CD81 and anti-CD151were used at 10 μg/ml, this was followed by incubation with FITC 
conjugated anti-mouse IgG. (A) The dot plot shows HEC1B cells gated according to forward 
scatter (FSC) and side scatter (SSC). (B) The histogram plot shows tetraspanin expression levels 
compared to the isotype control. (C) Median fluorescent intensity (MFI), error bars describe the 
standard error, N= 4, mean ± SEM. Data were analysed by One-way ANOVA with Dennett’s 
multiple comparison test, ****P < 0.0001, ns denotes not significant. 
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3.3 Discussion 
Tetraspanins including CD9, CD63, CD81, and CD151 are associated with cellular 
adhesion, signal transduction, migration and cell differentiation (Woegerbauer et al., 
2010). The aim of this chapter was to identify and quantify the expression of these 
tetraspanins in three cell lines A549 cells, HaCaT cells and HEC1B cells. 
Immunofluorescence staining and flow cytometry analysis of the three cell lines revealed 
that the tetraspanin CD9 was expressed at high levels in all cell lines under investigation 
compared to the isotype control cells, this makes all these cell lines appropriate models 
for studying the effect of tetraspanin CD9 EC2-derived peptides in P. aeruginosa 
adhesion. In addition, some tetraspanins such as CD63 and CD151 showed some variation 
between the three cell lines under study. Moreover, the expression levels of the 
tetraspanins in A549 and HEC1B cells were found to be similar with both 
immunofluorescent microscopy and flow cytometry, whereas the HaCaT cells showed 
different patterns of expression between the two methods. 
CD63 or Tetraspanin 30 was the first described tetraspanin (Pols and Klumperman, 2009) 
and it is mainly linked with the membranes of intracellular vesicles (Petersen et al., 2011). 
CD63 plays an important role in intracellular transport of other proteins (Berditchevski 
and Odintsova, 2007). CD151 or Tetraspanin 24 is well known for its role in enhancing 
cell motility and metastasis of cancer cells (Ashman et al., 1991). In this study, the 
expression of these tetraspanins appeared to vary considerably; the A549 epithelial cell 
line revealed high expression levels, the HaCaT keratinocyte cell line revealed only an 
intermediate level expression, and the expression was found to be very low in the HEC1B 
cell line. This implies that a different distribution may produce a specific tetraspanin 
subset for each cell line allowing the formation of cell-type specific TEMs and that 
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explains the different function of the tetraspanin in each cell line as proposed by a number 
of groups (Levy and Shoham, 2005a). 
Finally, CD81 or Tetraspanin 28 has been found to interact with immunoglobulin 
superfamily and is involved in many physiological functions (Levy, 2014; Clark et al., 
2001).  In this study, all cell lines were found to express a detectable level of CD81 but it 
was very high in the HaCaT cells. 
To summarise, the expression of tetraspanins was variable in the three cell lines tested, 
showing different localisation patterns. A549 cells and HEC1B cells showed a high level 
of expression of CD9, and this could potentially make them suitable target cells for CD9 
EC2-derived peptides therapies (chapter 6). Furthermore, chapter 5 will investigate the 
effect of recombinant tetraspanin EC2: GST proteins and anti-tetraspanin antibodies on 
P. aeruginosa adhesion to our tested cell lines.  
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CHAPTER 4: Use of flow cytometry to improve 
throughput in bacterial adhesion assays
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4.1 Introduction 
Flow cytometry is considered to be a useful tool in studying bacterial host binding and 
bacterial pathogenicity (Valdivia and Falkow, 1998; Pils et al., 2006b). It is a rapid 
method for investigating bacterial adhesion and invasion. For example, some flow 
cytometers (such as Attune) can analyse samples in a 96-well format.  Moreover, it allows 
the use of genetically or chemically tagged bacteria (Agerer et al., 2004; DeLoid et al., 
2009; Trouillet et al., 2011b). However, sometimes the use of modified bacteria may 
introduce artefacts when studying adhesion and invasion (Trouillet et al., 2011b). The 
purpose of this chapter is to investigate the usefulness of fluorescence microscopy as a 
replacement of manual counting by developing a flow cytometric method that can rapidly 
detect the adhesion of P. aeruginosa to a host cell. In order to achieve this aim, a 
fluorescent-labelled P. aeruginosa (PAO1) was constructed and characterised.  
 
The aims of this chapter: 
• To generate a fluorescent P. aeruginosa (green and red) by genetic modification. 
• To determine the optimum MOI for infection.  
• To develop a flow cytometric method (Attune FACS machine) that can detect the 
disruption of P. aeruginosa adhesion to host cells using tetraspanin reagents.  
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4.2 Results 
4.2.1 Construction of GFP and DsRed expressing P. aeruginosa 
The plasmids PIN25 (green) and PIN29 (red) were introduced into the P. aeruginosa 
strain PAO1 by electroporation. Firstly, we determined if there was any change in 
bacterial growth in the presence of the new plasmid. Bacterial growth was investigated 
by the measurement of the OD at 600 nm and CFU/ml count (section 2.2.2.2). No 
significant changes were observed between the wild type and transformed bacteria 
(Figure 4.1). Secondly, P. aeruginosa was found to be successfully labelled with both 
plasmids (PIN25 and PIN29) as shown in Figure.4.2. There was a ~100-fold increase in 
the fluorescence of GFP-labelled P. aeruginosa and DsRed-labelled P. aeruginosa 
compared to the unlabelled P. aeruginosa (Figure 4.2). Finally, attachment of the 
fluorescent and non-fluorescent bacteria to A549 cells was analysed by flow cytometry 
(Figures 4.3) and the percentage of positive fluorescent bacteria compared with non-
transformed wild type bacteria was measured using flow cytometry, and compared to the 
non-transformed bacteria (Figures 4.4). Moreover, the fluorescent bacteria were clearly 
visualised using fluorescence microscopy as shown in Figure 4.5.  
The fluorescent bacteria were clearly detectable using both methods. However, GFP-
labelled P. aeruginosa was used through this study as the DsRed-labelled P. aeruginosa 
was found to be more susceptible to photo bleaching.  
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Figure 4.1 Growth curve of GFP-labelled P. aeruginosa and DsRed-labelled P. 
aeruginosa over time in LB medium.   
Overnight cultures of GFP-labelled P. aeruginosa and DsRed-labelled P. aeruginosa were diluted 
to an OD600 of 0.05 and grown in LB medium at 37°C for 24 hours, with agitation at 120 rpm. 
OD was measured at 600 nm, N= 3. 
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Figure 4.2 Flow cytometric analysis of labelled GFP and DsRed labelled P. 
aeruginosa. 
(A) Distribution of unlabelled bacteria in the dot plot display of forward scatter (FCS) vs side 
scatter (SSC) (left panel) and frequency plot (right panel). (B) Labelled bacteria frequency plots 
for GFP (left panel) and DsRed (right panel). The efficiency of the labelling was analysed by 
measuring the fluorescence of the bacteria on channel BL1 for GFP (green) and BL2 for DsRed 
(red). The labelling of the bacteria is seen as a shift of the bacteria along the BL1 and BL2 axes 
in the frequency plots. The data were analysed by the Attune FACS machine. 
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Figure 4.3 Quantifying the adhesion of fluorescent GFP and DsRed-labelled P. 
aeruginosa to A549 cells by flow cytometry. 
Analysis of the green (PIN25) and red (PIN29) transformed P. aeruginosa by flow cytometry 
using Attune FACS machine. (A) Dot plot showing cells without infection and (B) cells infected 
with GFP-labelled P. aeruginosa using the filter BL-1 to detect GFP (530/30 nm), and (C) cells 
infected with DsRed-labelled P. aeruginosa using the filter BL-2 to detect DsRed (574/26 nm).  
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Figure 4.4 Flow cytometric analysis of fluorescent GFP and DsRed-labelled P. 
aeruginosa. 
The percentage of positive fluorescent bacteria compared with non-transformed wild type was 
measured using flow cytometry and compared to the non-transformed bacteria. (A) The 
percentage of GFP-labelled P. aeruginosa. (B) The percentage of DsRed-labelled P. aeruginosa. 
Data were analysed using One-way ANOVA test, ***P ≤ 0.001, N= 3. Results are mean ± 
standard error of the mean (SEM). 
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Figure 4.5 Immunofluorescence images of fluorescent labelled P. aeruginosa 
transformed with GFP and DsRed plasmid.  
P. aeruginosa were cultured and prepared for microscopic imaging (section 2.2.3). (A) 
Transformed GFP-labelled P. aeruginosa (green) visualised using FITC filter and (B) 
Transformed DsRed-labelled P. aeruginosa (red) visualised using the Texas red filter. Images 
were obtained by fluorescence microscopy using the 100 x objective, the scale bar represents 7 
μm.  
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4.2.2 Optimising the multiplicity of infection (MOI) 
In order to study the adhesion of P. aeruginosa to the host cell, a range of MOIs were 
tested to determine the optimum MOI that gives 50 % maximal fluorescence of infected 
cells. GFP-labelled P. aeruginosa was used to infect the A549 cell line at serial bacterial 
dilutions and the degree of fluorescence obtained in flow cytometry was plotted in order 
to determine the optimal MOI (Figure 4.6). MOI of 35 was found to be the optimum MOI 
for flow cytometry infection (Figure 4.7). This optimisation was carried out for HaCaT 
cells and HEC1B cells using a similar method (data not shown). 
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Figure 4.6 Flow cytometric analysis of A549 cells infected with GFP-labelled P. 
aeruginosa at MOIs of 5, 35 and 50. 
A549 cells were incubated with GFP-labelled P. aeruginosa for 60 minutes at a range of MOIs 
followed by fixation and flow cytometry analysis using the Attune FACS machine, N= 4. The dot 
plots show region R1 showing positively fluorescent GFP-labelled P. aeruginosa. (A) MOI 5:1, 
(B) MOI 35:1 and (C) MOI 50:1. 
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Figure 4.7 Flow cytometric analysis of optimum MOI on the attachment of GFP-
labelled P. aeruginosa to A549 cells. 
A549 cells were incubated with GFP-labelled P. aeruginosa for 60 minutes at a range of MOIs 
followed by fixation and flow cytometry analysis. (A) The percentage of positive fluorescent 
A549 cells. (B) The median fluorescence intensity (MFI). A549 cells were analysed using Attune 
FACS machine, N= 4. 
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4.2.3 The effect of tetraspanin treatments on GFP-labelled P. aeruginosa 
adhesion analysed by flow cytometry 
The results in section 4.3.1 demonstrated the potential of using flow cytometry for 
detection of bacterial binding instead of using the conventional immunofluorescent 
microscopy method. Flow cytometry is a faster method of detection that can screen a 
large number of cells associated with bacteria, whereas microscopy requires manual 
counting of cells, thus it takes longer time and a lesser number of cells with associated 
bacteria are counted.  
GFP-labelled P. aeruginosa were prepared for infection as previously described (section 
2.2.3). The main difference in the procedure afterwards was that cells were harvested, 
subjected to tetraspanin treatments in a 96-well plate and then infected with the bacteria 
(section 2.2.5). Optimisation experiments were carried out for each cell line. Interestingly, 
the overall optimisation results showed that a higher MOI was needed to give a sufficient 
number of infected cells for the host cell lines to be detected by flow cytometry (section 
4.3.2). Tetraspanin treatments were then screened using this method.  
All data were normalised to the mean of the control (isotype for anti-tetraspanin 
antibodies / GST for EC2 proteins treatment) to compensate for the effect of the variation 
between the experiments.  
4.2.3.1 The effects of anti-tetraspanin antibodies on GFP-labelled P. aeruginosa 
adherence to A549 cells 
The A549 epithelial cell line was used because the A549 cells offer a useful epithelial cell 
model for the investigation of P. aeruginosa infection (Ramphal et al., 1991; Hawdon et 
al., 2010; Ahmed et al., 2014). After treatment with anti-tetraspanin antibodies - anti-
CD9, anti-CD63, anti-CD81 and anti-CD151, or isotype control at a concentration of 10 
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μg /ml for 30 minutes, the A549 cells were infected with GFP-labelled P. aeruginosa at 
MOI of 35 for 60 minutes using the flow cytometry protocol for infection as described in 
detail in section 2.2.5. The isotype control antibody was used to determine a possible 
effect of nonspecific binding of the antibody. The antibody was used at 10 μg /ml because 
this concentration is known to give saturating binding (Ali, 2016; Elgawidi, 2016). The 
cells were analysed using the Attune FACS machine and 10,000 events were acquired. 
The cells were gated depending on forward and side scatter (FSC and SSC respectively), 
and for detecting cells associated with bacteria, the blue 488 laser (BL-1) was used to 
distinguish the FITC signal (Figure 4.8 A), which was clearly above the auto-fluorescent 
background signals from the cells. The percentage of positive fluorescent cells reveals 
the cells with binding bacteria whilst the MFI shows the intensity of bacterial infection.  
The flow cytometry method showed a slight inhibition of GFP-labelled P. aeruginosa 
adhesion to A549 cells pre-treated with the anti-CD9 antibody (Figure 4.8 B). However, 
no significant reduction in the percentage of infection rate was seen in cells pre-treated 
with anti-CD81, anti-CD63 and anti-CD151 antibodies compared to the isotype control 
cells (Figure 4.9 A.). Moreover, a similar pattern was seen in terms of median fluorescent 
intensity (Figure 4.9 B).  
4.2.3.2 The effects of EC2: GST proteins on GFP-labelled P. aeruginosa adherence 
to A549 cells 
The flow cytometry method was used to investigate the effect of EC2: GST proteins on 
adhesion of GFP-labelled P. aeruginosa to A549 cells. After treatment with EC2: GST 
proteins - CD9, CD63, CD81 and CD151, or GST control at a aconcentration of 500 nM 
for 30 minutes, the cells were infected with GFP-labelled P. aeruginosa at MOI of 35 for 
60 minutes using the flow cytometry protocol for infection as described in detail in section 
2.2.5, similar to the antibodies treatment method. A minor significant change in the 
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percentage of fluorescent A549 cells was observed when cells were pre-treated with 
CD81 compared to the GST control (Figure 4.10 A). While, no significant effect was 
observed when cells were pre-treated with CD9, CD63 and CD151 compared to the GST 
control (Figure 4.10 A). Also, a significant reduction was observed in the median 
fluorescent intensity of GFP-labelled P. aeruginosa adhesion in the cells that were pre-
treated with CD81 prior to infection compared to the GST control cells (Figure 4.10 B). 
However, no significant effect was observed when the cells were pre-treated with CD9, 
CD63 and CD151 compared to the GST control cells (Figure 4.10 B). 
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Figure 4.8 The flow cytometric detection of the effects of anti-CD9 antibody on GFP-
labelled P. aeruginosa adherence to A549 cells. 
A549 cells were pre-treated with anti-tetraspanin antibodies - anti-CD9 or isotype control at 10 
μg /ml for 30 minutes before infection with GFP-labelled P. aeruginosa as described in 2.2.5. The 
analysis was done using the Attune FACS machine. (A) Dot plot analysis showing the gated 
population of A549 cells analysed based on forward and side scatter, with the region R1 showing 
the percentage of positively fluorescent cells. (B) The percentage of A549 cells after treatment 
with isotype control (left) or anti-CD9 (right) followed by infection with GFP-labelled P. 
aeruginosa. 
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Figure 4.9 The flow cytometric detection of the effects of anti-tetraspanin antibodies 
on GFP-labelled P. aeruginosa adherence to A549 cells. 
A549 cells were pre-treated with anti-tetraspanin antibodies - anti-CD9, anti-CD63, anti-CD81 
and anti-CD151, or isotype control at 10 μg /ml for 30 minutes before infection with GFP-labelled 
P. aeruginosa as described in 2.2.5. The analysis was done using the Attune FACS machine. (A) 
The percentage of A549 cells infected with GFP-labelled P. aeruginosa normalised to 100 % 
isotype control. (B) The median fluorescent intensity (MFI) normalised to 100 % isotype control. 
Results are mean ± standard error of the mean (SEM), N= 4. Data were analysed using One-way 
ANOVA (vs. isotype control), *P ≤ 0.1 and ns is non-significant. 
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Figure 4.10 The flow cytometric detection of the effects of EC2: GST proteins on 
GFP-labelled P. aeruginosa adherence to A549 cells. 
A549 cells were pre-treated with EC2: GST proteins - CD9, CD63, CD81 and CD151, or GST 
control at 500 nM for 30 minutes before infection with GFP-labelled P. aeruginosa as described 
in 2.2.5. The analysis was done using the Attune FACS machine. (A) The percentage of A549 
cells infected with GFP-labelled P. aeruginosa normalised to 100 % GST control. (B) The median 
fluorescent intensity normalised to 100 % GST control. Results are mean ± standard error of the 
mean (SEM), N= 4. Data were analysed using One-way ANOVA (vs. GST control), **P ≤ 0.01, 
*P ≤ 0.1 and ns are non-significant.  
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4.2.3.3 The effects of anti-tetraspanin antibodies on GFP-labelled P. aeruginosa 
adherence to HaCaT cells 
The HaCaT keratinocyte cell line was also investigated because the HaCaT cells are 
considered a model for P. aeruginosa infection (Lee et al., 2016). From the initial 
optimising experiments, MOI of 35 for 60 minutes was chosen (data not shown). HaCaT 
cells pre-treated with anti-CD9 showed a significant reduction of GFP-labelled P. 
aeruginosa adhesion compared to the isotype control cells (Figure 4.11 A). While, no 
significant reduction was seen in the percentage of cells pre-treated with anti-CD63, anti-
CD81 and anti-CD151 compared to the isotype control cells (Figure 4.11 A). In addition, 
in terms of median fluorescent intensity, similar patterns were observed (Figure 4.11 B). 
4.2.3.4 The effects of EC2: GST proteins on GFP-labelled P. aeruginosa adherence 
to HaCaT cells 
The effects of EC2: GST proteins were also investigated in HaCaT cells. Here, CD9 
reduced the bacterial association of cells infected with the GFP-labelled P. aeruginosa 
whilst no significant effects were noticed with any other EC2: GST protein treatments 
compared to the GST control cells (Figure 4.12 A). Additionally, similar patterns were 
observed in terms of the median fluorescent intensity (Figure 4.12 B).  
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Figure 4.11 The flow cytometric detection of the effects of anti-tetraspanin 
antibodies on GFP-labelled P. aeruginosa adherence to HaCaT cells. 
HaCaT cells were pre-treated with anti-tetraspanin antibodies - anti-CD9, anti-CD63, anti-CD81 
and anti-CD151, or isotype control at 10 μg /ml for 30 minutes before infection with GFP-labelled 
P. aeruginosa as described in 2.2.5. The analysis was done using the Attune FACS machine. (A) 
The percentage of HaCaT cells infected with GFP-labelled P. aeruginosa normalised to 100 % 
isotype control. (B) The median fluorescent intensity normalised to 100 % isotype control. Results 
are mean ± standard error of the mean (SEM), N= 4. Data were analysed using One-way ANOVA 
(vs. isotype control), *P ≤ 0.1 and ns is non-significant. 
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Figure 4.12 The flow cytometric detection of the effects of EC2: GST proteins on 
GFP-labelled P. aeruginosa adherence to HaCaT cells. 
HaCaT cells were pre-treated with EC2: GST proteins - CD9, CD63, CD81 and CD151, or GST 
control at 500 nM for 30 minutes before infection with GFP-labelled P. aeruginosa as described 
in 2.2.5. The analysis was done using the Attune FACS machine. (A) The percentage of HaCaT 
cells infected with GFP-labelled P. aeruginosa normalised to 100 % GST control. (B) The median 
fluorescent intensity normalised to 100 % GST control. Results are mean ± standard error of the 
mean (SEM), N= 4. Data were analysed using One-way ANOVA (vs. GST control), *P ≤ 0.1 and 
ns is non-significant.  
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4.2.3.5 The effects of anti-tetraspanin antibodies on GFP-labelled P. aeruginosa 
adherence to HEC1B cells 
Alongside with A549 cells and HaCaT cells, another epithelial cell line was used. The 
HEC1B cell line is a common model for Gram-negative bacteria infection studies (Miller 
and Falkow, 1988; Spence et al., 1997; Spence and Clark, 2000). Additionally, in the 
previous chapter 3, the HEC1B cells were found to have a high expression level of 
tetraspanins CD9 and CD81, and this makes them a useful cell model for investigation. 
Optimisation experiments indicated that an MOI of 35 and an infection time of 60 minutes 
were suitable (data not shown). As previously (section 4.3.3.1), HEC1B cells were pre-
treated with anti tetraspanins antibodies prior to infection. As shown in Figure 4.13, none 
of the anti-tetraspanin antibodies tested reduced adhesion of the cells infected with GFP-
labelled P. aeruginosa either in the percentage of fluorescent cells (Figure 4.13 A) or as 
a median fluorescent intensity (Figure 4.13 B). 
4.2.3.6 The effects of EC2: GST proteins on GFP-labelled P. aeruginosa adherence 
to HEC1B cells 
The effects of EC2: GST proteins were investigated as described previously (2.2.5). None 
of the EC2: GST proteins affected the percentage of GFP-labelled P. aeruginosa adhesion 
to pre-treated HEC1B cells (Figure 4.14 A). Moreover, no significant changes in the 
median fluorescent intensity were observed (Figure 4.14 B). 
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Figure 4.13 The flow cytometric detection of the effects of anti-tetraspanin 
antibodies on GFP-labelled P. aeruginosa adherence to HEC1B cells. 
HEC1B cells were pre-treated with anti-tetraspanin antibodies - anti-CD9, anti-CD63, anti-CD81 
and anti-CD151, or isotype control at 10 μg /ml for 30 minutes before infection with GFP-labelled 
P. aeruginosa as described in section 2.2.5. The analysis was done using the Attune FACS 
machine. (A) The percentage of HEC1B cells infected with GFP-labelled P. aeruginosa 
normalised to 100 % isotype control. (B) The median fluorescent intensity normalised to 100 % 
isotype control. Results are mean ± standard error of the mean (SEM), N= 4. Data were analysed 
using One-way ANOVA (vs. isotype control), ns is non-significant. 
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Figure 4.14 The flow cytometric detection of the effects of EC2: GST proteins on 
GFP-labelled P. aeruginosa adherence to HEC1B cells. 
HEC1B cells were pre-treated with EC2: GST proteins - CD9, CD63, CD81 and CD151, or GST 
control at 500 nM for 30 minutes before infection with GFP-labelled P. aeruginosa as described 
in 2.2.5. The analysis was done using the Attune FACS machine. (A) The percentage of HEC1B 
cells infected with GFP-labelled P. aeruginosa normalised to 100 % GST control. (B) The median 
fluorescent intensity normalised to 100 % GST control. Results are mean ± standard error of the 
mean (SEM), N= 4. Data were analysed using One-way ANOVA (vs. GST control), ns is non-
significant.  
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4.2.4 Comparison between microscopy and flow cytometry 
The flow cytometry method was shown to be able to detect bacterial infection. A 
comparison study was then carried out between flow cytometry and the classical method 
(immunofluorescent microscopy) using a positive control (S. aureus). This was done to 
assess the suitability of flow cytometry as an alternative and high-throughput method of 
detecting bacterial adhesion. Data was acquired by a previous PhD student from our group 
(Ventress et al., 2016) who investigated the effects of EC2: GST proteins on S. aureus 
adhesion to HaCaT cells by immunofluorescent microscopy. Briefly, cells were incubated 
with EC2: GST proteins or GST control at 500 nM for 30 minutes prior to the introduction 
of the GFP-labelled S. aureus for 60 minutes. Fluorescent microscopy examination 
demonstrated that HaCaT cells pre-treated with EC2: GST proteins CD9 and CD81 
significantly reduced the percentage of HaCaT cells with adherent bacteria by 88 % and 
90 % respectively (Figure 4.15 A). Moreover, fluorescent microscopy analysis showed 
that pre-treatment with CD9 and CD81 reduced (to 43 % and 42 % respectively) the 
number of adherent bacteria per 100 cells vs GST control cells (Figure 4.15 B). On 
another hand, the use of flow cytometry method for the same pathogen and cell line 
showed different results. There was no significant reduction found in terms of the 
percentage of fluorescent cells pre-treated with CD9 and CD81 EC2: GST proteins 
(Figure 4.15 C). Furthermore, no significant reduction was seen in the median fluorescent 
intensity of cells pre-treated with CD9 and there was only a small but significant reduction 
in cells pre-treated with CD81 (18 %) of adherent bacteria vs GST control cells (Figure 
4.15 D).  
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Figure 4.15 The effect of EC2: GST fusion proteins on GFP-labelled S. aureus 
adherence to HaCaT cells using fluorescent microscopy and flow cytometry. 
HaCaT cells were pre-treated with EC2: GST proteins at 500 nM for 30 minutes before the 
infection with GFP-labelled S. aureus for 60 minutes. (A) The percentage of cells with adherent 
bacteria. (B) The percentage of change in bacteria per 100 cells, (A and B) were measured using 
fluorescent microscopy, N= 5. (C) The percentage of positive fluorescent cells. (D) The median 
fluorescent intensity (MFI) normalised to (100) GST control, (C and D) adhesion measured by 
flow cytometry, N=4. Data were analysed using One way ANOVA with Sidak’s multiple 
comparisons test (vs. GST control), *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001 and ns 
is non-significant.  
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4.3 Discussion 
The aim of this chapter was to develop a rapid method for detecting bacterial adhesion, 
which could then be used to investigate the effects of tetraspanin treatments on the 
adhesion of P. aeruginosa to the host cell. P. aeruginosa was successfully labelled with 
both plasmids (PIN25 and PIN29) and the fluorescent-labelled P. aeruginosa were 
detected by flow cytometry. The role of tetraspanin treatments in the adhesion of GFP-
labelled P. aeruginosa to the host cell was then investigated using flow cytometry. 
Furthermore, the comparison between flow cytometry method and fluorescent 
microscopy was also investigated.  
Flow cytometry is a technique that can potentially be used to produce faster quantitative 
results, particularly if a 96-well plate can be used to input samples. The flow cytometer 
detects both extracellular and intracellular bacteria that are associated with the host cell 
(i.e. infected cell). This is due to the fact that data acquisition is triggered by the host cells, 
which are selectively identified based upon their side and forward light scatter properties. 
Therefore, a cell is recognised as either non-fluorescent (not infected) or with a variable 
strength of the fluorescence signal based on the number of adherent or internalised 
fluorescent bacteria. Thus, flow cytometry could give an estimate of the total number of 
extracellular and intracellular labelled bacteria.  
HaCaT cells treated with EC2: GST proteins prior to infection with GFP-labelled S. 
aureus showed different results between the flow cytometry method and the fluorescent 
microscopy method. Using fluorescent microscopy revealed there was a significant 
inhibition of GFP-labelled S. aureus adhesion when HaCaT cells were pretreated with the 
EC2: GST proteins CD9 and CD81, while, flow cytometry showed no significant effect 
of the EC2: GST proteins on GFP-labelled S. aureus adhesion to HaCaT cells. 
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Additionally, using flow cytometry analysis to investigate the effect of tetraspanins 
treatment on the adhesion of GFP-labelled P. aeruginosa to the host cells showed 
different results compared with the investigation by fluorescent microscopy (chapter 5). 
A slight reduction in the number of GFP-labelled P. aeruginosa attached to the host cells 
was found by flow cytometry when the cells were pre-treated with anti-tetraspanin 
antibodies or EC2: GST proteins. For example; in the A549 and HaCaT cells, the pre-
treatment with tetraspanin CD9 resulted in a slight inhibition of the GFP-labelled P. 
aeruginosa adhesion, and no significant inhibition was seen when HEC1B cells were pre-
treated with any of the tetraspanins under investigation. Whereas, fluorescent microscopy 
showed a significant effect of the tetraspanin CD9 on the adhesion of GFP-labelled P. 
aeruginosa to A549, HaCaT and HEC1B cells. Moreover, recent work by our group to 
investigate the effect of tetraspanin CD9 derived peptides on reducing GFP-labelled S. 
aureus adherence to HaCaT cells using flow cytometry showed no significant effect of 
any of the peptides tested, whereas with fluorescent microscopy a significant effect was 
seen to inhibited GFP-labelled S. aureus adherence to HaCaT cells (unpublished 
observations by our group). Also, previous work by our group investigated the effect of 
tetraspanin CD9 peptides treatment on GFP-labelled S. aureus adhesion to HaCaT cells 
by flow cytometry and fluorescent microscopy. No significant effect was observed on 
GFP-labelled S. aureus adherence to pre-treated HaCaT cells by flow cytometry, whereas 
a significant effect was seen by fluorescent microscopy (Ventress, 2016). 
This indicates that flow cytometry might not be a suitable/ sensitive method to measure 
changes in fluorescent labelled bacterial adhesion. A possible reason for this observation 
is that in flow cytometry a higher MOI was required to achieve the infection that in turn 
could be detected by the GFP fluorescent signal. The use of such high MOIs may have 
altered the efficiency of antibody/EC2 treatments (Ventress, 2016). In addition, the 
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mechanical stress of the assay is likely to have removed some of the adherent bacteria or 
maybe the overlap between the bacterial analysis with the background fluorescent and the 
host cell (Grootaert et al., 2011). This result is consistent with the previous findings by 
Vesterlund et al., (2005), who found that a high signal-to-background ratio, particularly 
when the cell surface is auto fluorescent, results in low sensitivity in detection of the 
adherent bacteria by flow cytometry. Another reason could be the difficulty of 
distinguishing between the live and dead bacteria adherent to a monolayer of 
differentiated cell lines (Grootaert et al., 2011). 
Commonly used methods to detect the majority of the pathogenic microbes may involve 
microscopical counting, plating (Entis et al., 2001), Q-PCR, rediolabelling of the bacteria, 
or the enzyme-linked immunosorbent assay (ELISA) (Bernet et al., 1994; Ouwehand et 
al., 2001). However, it is important to note that these methods of detection require the 
bacteria to be viable and culturable, and this limits the detection to a specific physiological 
state (Harkins and Harrigan, 2004). These methods may lead to false negative results, or 
to the number of pathogens within the given sample may be underestimated (Vora et al., 
2004; Lazcka et al., 2007). They cannot provide the required information regarding the 
pathogenicity or the virulence of the pathogen identified.  
Therefore, efforts have been made to develop a rapid flow cytometry -based method, 
which can rapidly detect a lower concentration of the pathogens (Hammes et al., 2008; 
Riyaz-Ul-Hassan et al., 2008; Lautenschlager et al., 2013).  
 Infectious pathogens of concern for flow cytometry analysis include viruses, for example 
rotavirus (Kandasamy et al., 2016) and the human immunodeficiency virus type 1 
(Venereo-Sanchez et al., 2017). Bacteria such as Salmonella (Wahid et al., 2016), S. 
aureus (Kennedy and Wilkinson, 2017; Meng et al., 2017), fungi such as Aspergillus and 
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Candida (Yun and Lee, 2017) are also target for flow cytometry. However, many issues 
may complicate the identification of the target microorganism such as the difficulties to 
distinguish between some particles as inorganic debris and the microorganism spores. 
Thus, flow cytometry assay could be a potentially sensitive, rapid and suitable method 
for immediate detection of pathological agents (multiplex analysis) (Zahavy et al., 2012). 
Flow cytometry analysis offers investigators the ability to obtain many data for an 
individual cell (Winson and Davey, 2000). This method generates data about cell 
viability, physiological status or period of the growth cycle. Furthermore, flow cytometers 
can analyse thousands of cells/events per second. 
A number of publications have reported the increasing uses of flow cytometry as an 
alternative method for detection of pathogenic microorganisms (Berney et al., 2006; 
Cronin and Wilkinson, 2007; Allegra et al., 2008; Jarzembowski et al., 2008; Ryumae et 
al., 2010; Nocker et al., 2011). GFP has been widely used as a fluorescent indicator in 
investigating bacterial interaction with host cells in both imaging and quantification 
studies (Sabuquillo et al., 2017). Many previous studies have used flow cytometry 
detection to measure bacterial infection, for example, GFP-expressing P. fluorescens 
(Tombolini et al., 1997) and genetically labelled L. monocytogenes (Raybourne et al., 
2001). The use of fluorescent-labelled bacteria enables reproducible enumeration of 
internalised and adherent bacteria (Vesterlund et al., 2005). Furthermore, flow cytometry 
has many uses, it has been recently approved for the analysis of bacterial attachment to 
host cells (Hytönen et al., 2006a). In addition, Sethman et al., (2002) have used the flow 
cytometric assay to assign functions to individual surface molecules through distinct 
phases of adhesion. In another study, flow cytometry was used to investigate the immune 
response against intracellular bacteria (Karanikas et al., 2000). These examples show that 
flow cytometry can be used for a variety of research investigations. 
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The main limitation in analysing bacteria using flow cytometry is that many of their 
natural characteristics (such as shape, size and DNA content) differ depending on the 
growth conditions used, or the sources from which the bacteria were taken (Winson and 
Davey, 2000). Therefore, in order to produce consistent data, strict reproducibility of the 
conditions is required. Moreover, in some investigations a specific type of flow cytometry 
is required, such as in the study of bacteria that generate an aerosol, the flow cytometry 
has to have a filter to control this concern and the biosafety levels required will differ 
with the type of sorting being carried out (Schmid et al., 2007). Additionally, bacteria are 
much smaller than human cells; therefore, the analysis of pathogenic bacteria poses 
specific challenges for flow cytometry. Furthermore, if the flow cytometry machine is not 
specifically designed for microbial investigation, it is necessary to determine whether it 
is capable of such analysis and then optimise its performance (Harkins and Harrigan, 
2004). 
In flow cytometry, using the two-parameter histogram side-scatter and forward scatter, 
the fluorescence and ratio information allows the user to identify the location of the 
labelled pathogens on a two-parameter histogram. Using flow cytometry to analyse 
bacterial population is common, however, to develop and adjust flow cytometers to the 
detection of a specific bacterial pathogen is still uncommon. 
In summary, fluorescent-labelled P. aeruginosa were constructed and a flow cytometry-
based assay was developed for monitoring fluorescent-labelled P. aeruginosa infection. 
However, the fluorescent detection of flow cytometry is weaker than the microscopy 
assay. This could be due to the low fluorescence of intracellular fluorescent -expressing 
bacteria, or because of the use of GFP fluorescent labelling which may introduce a bias 
when measuring fine differences in adhesion (Trouillet et al., 2011b). Moreover, higher 
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MOI was required for flow cytometry and that may have affected the assay. Due to this, 
thereafter in this work, the fluorescent microscopy method was used to investigate the 
role of tetraspanin treatments on GFP-labelled P. aeruginosa adhesion to the host cells. 
  
  
 
102 
 
 
 
 
 
 
 
CHAPTER 5: The effect of tetraspanin EC2: GST 
proteins and anti-tetraspanin antibodies on P. 
aeruginosa adhesion to human cell
  
 
103 
5.1 Introduction 
Infection of host tissues is commonly initiated by adherence of bacteria to membrane 
proteins, sugars or lipids on the cell surface. However, for full functionality, membrane 
proteins are usually organised into microdomains, such as TEM. Tetraspanins such as 
CD9, CD81, CD63 and CD151 are a class of proteins known to play a major role in TEM 
organisation and thus they are potential targets for the inhibition of bacterial adhesion to 
host cells. 
Monoclonal antibodies (mAbs) targeting cell surface proteins are potent tools that have 
been largely used in diagnostic, therapeutic and research studies. Previously, anti-
tetraspanin antibodies have been used to identify the functions of various tetrasapnins 
(Tachibana and Hemler, 1999; Kaji et al., 2000).  
The dependence of multiple bacterial target molecules on tetraspanins, our proteins of 
interest, suggests that tetraspanin reagents could be useful as therapeutic strategies to alter 
these relationships in order to prevent or treat bacterial infections, and this hypothesis is 
explored in this chapter. 
 
The aims of this chapter: 
• To determine the effects of tetraspanin reagents on P. aeruginosa adhesion to 
human cells. 
• To assess the effect of bacterial lipopolysaccharide (LPS) on the functional 
activity of the recombinant EC2 proteins treatment.  
• To explore the ability of anti-tetraspanin antibodies to protect A549 and HEC1B 
cells against P. aeruginosa-induced cytotoxicity using the LDH assay. 
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5.2 Results 
5.2.1 The effect of anti-tetraspanin antibodies on GFP-labelled P. aeruginosa 
adhesion to host cells 
Flow cytometry was shown in Chapter 4 to be a weak method for detection of inhibitors 
of bacterial attachment, therefore only immunofluorescent microscopy was used to 
investigate the effect of tetraspanin treatments on GFP-labelled P. aeruginosa adhesion 
to the host cell through this study. In order to investigate the effect of anti tetraspanin 
antibodies on GFP-labelled P. aeruginosa, the human cells were incubated with anti-
tetraspanin antibodies or the isotype control prior to the introduction of GFP-labelled P. 
aeruginosa.  
5.2.1.1 Optimising the conditions for GFP-labelled P. aeruginosa infection assay 
The following method was taken from (Ali, 2016).  Tetraspanins expression in the cell 
lines used in this study has been described previously (chapter 3). Other initial 
experiments included studying the GFP-labelled P. aeruginosa growth curve to find the 
log phase that would be used. Different multiplicities of infection (MOIs) and infection 
times were examined to find the most suitable ones. A growth curve was plotted by 
growing GFP-labelled P. aeruginosa in LB broth and measuring both optical density 
(OD600nm) and viable bacterial counts (colony forming unit - CFU) during different time 
periods (1 - 24 hours). This experiment was repeated three times and the mid-log phase 
was chosen from the average to be used for the GFP-labelled P. aeruginosa infection 
assay (OD600nm ≈ 0.5, time ≈ 60 minutes and CFU≈ 5 x108) (data not shown). For further 
validation, the CFU was measured separately for each experiment. To optimise the MOI 
and infection time, the various human cell lines were infected at different MOIs (5, 10, 
20, 30 and 50) and for different times (30, 40, 60 and 90 minutes). The human cells were 
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fixed, stained and counted (section 2.2.4). High MOIs and longer incubation times gave 
high infection rates and high numbers of bacteria that made counting very difficult, 
whereas shorter times gave low rates of infection with less bacterial internalisation. The 
experiments revealed that for the three cell lines used, an MOI of 10 and infection time 
of 60 minutes were the most appropriate (optimisation data not shown). 
5.2.1.2 The effect of anti-tetraspanin antibodies on GFP-labelled P. aeruginosa 
adhesion to A549 epithelial cells 
In all the experiments, it is possible that the anti-tetraspanin antibodies used to block the 
surface tetraspanins antigens will bind non-specifically with Fc receptors (FcR) that are 
expressed by these cells. Therefore, an appropriate isotype control was included to take 
account of the nonspecific binding of anti-tetraspanin antibodies to FcR. The effect of 
anti-tetraspanin antibodies on infection of A549 cells with GFP-labelled P. aeruginosa 
was assessed using saturating concentrations of antibody (10µg/ml) (section 2.2.6).  The 
antibody effects were measured by three parameters: the percentage of cells with 
associated bacteria, the change in the number of bacteria per 100 cells and the change in 
number of bacteria per infected cells calculated as described in section 2.2.4.3 
Immunofluorescence microscopy of A549 cells infected with GFP-labelled P. aeruginosa 
was used for counting. After 60 minutes of infection, the percentage of cells associated 
with GFP-labelled P. aeruginosa was significantly reduced after pre-treatment with anti-
CD151 (50 %), anti-CD9 (48 %), anti-CD63 (42 %) and anti-CD81 (30 %), when 
compared to the isotype control (Figure 5.1 A). Moreover, a significant reduction was 
observed in terms of the number of GFP-labelled P. aeruginosa associated with epithelial 
cells pre-treated with anti-CD9 (62 %), anti-CD81 (54 %), anti-CD151 (42 %) and anti-
CD63 (34 %) antibodies compared to the isotype control cells as shown in Figure 5.1 B. 
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Also, there was no significant reduction in the number of GFP-labelled P. aeruginosa per 
infected cell, compared to the isotype control see Figure 5.1 C. 
 
 
Figure 5.1 The effect of anti-tetraspanin antibodies on GFP-labelled P. aeruginosa 
adherence to A549 epithelial cells.  
A549 cells were pre-treated with anti-tetraspanin antibodies (10 μg/ml) or the isotype control 
antibody for 30 minutes. GFP-labelled P. aeruginosa was incubated with adherent cells at MOI 
of 10 for 60 minutes, the cells were fixed, stained, then visualised using fluorescence microscopy 
and the number of infected cells was counted. (A) The percentage of cells with adherent bacteria. 
(B) The change in the number of bacteria per 100 cells. (C) The change in number of bacteria per 
infected cells, calculated as described in section 2.2.4, Results are mean ± standard error of the 
mean (SEM), N= 4. Data were analysed using One-way ANOVA with Sidak’s multiple 
comparisons test (vs. isotype control), * P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.000, 
ns is non-significant.  
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5.2.1.2 The effect of anti-tetraspanin antibodies on GFP-labelled P. aeruginosa 
adhesion to HaCaT keratinocyte cells 
The immunofluorescence microscopy of HaCaT cells infected with GFP-labelled P. 
aeruginosa was used for counting. After 60 minutes of infection, the percentage of cells 
associated with bacteria was significantly reduced after pre-treatment with anti-CD151 
(70 %), anti-CD9 (65 %), anti-CD63 (64 %) and anti-CD81 (48 %), when compared to 
the isotype control (Figure 5.2 A). Moreover, a significant reduction was observed in 
terms of the number of bacteria associated with keratinocyte cells pre-treated with anti-
CD9 (83 %), anti-CD151 (36 %), anti-CD63 (35 %) and anti-CD81 (6 %), antibodies 
compared to the isotype control cells as shown in Figure 5.2 B. Furthermore, there was 
no significant reduction in the number of bacteria per infected cells, compared to the 
isotype control (Figure 5.2 C). 
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Figure 5.2 The effect of anti-tetraspanin antibodies on GFP-labelled P. aeruginosa 
adherence to HaCaT cells.  
 
HaCaT cells were pre-treated with anti-tetraspanin antibodies (10 μg/ml) or the isotype control 
antibody for 30 minutes. GFP-labelled P. aeruginosa was incubated with adherent cells at MOI 
of 10 for 60 minutes, the cells were fixed, stained, then visualised using fluorescence microscopy 
and the number of infected cells was counted. (A) The percentage of cells with adherent bacteria. 
(B) The change in the number of bacteria per 100 cells. (C) The change in number of bacteria per 
infected cells, calculated as described in section 2.2.4, Results are mean ± standard error of the 
mean (SEM), N= 4. Data were analysed using One-way ANOVA with Sidak’s multiple 
comparisons test (vs. isotype control), *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001, ns is non-
significant.  
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5.2.1.3 The effect of anti-tetraspanin antibodies on GFP-labelled P. aeruginosa 
adhesion to HEC1B endometrial cells 
The immunofluorescence microscopy of HaCaT cells infected with GFP-labelled P. 
aeruginosa was used for counting. After 60 minutes of infection, the percentage of cells 
associated with bacteria was significantly reduced after pre-treatment with anti-
CD151(50 %), anti-CD9 (48 %), anti-CD63 (43 %) and anti-CD81 (30 %), when 
compared to the isotype control (Figure 5.3 A). Likewise, a significant reduction was 
observed in terms of the number of the bacteria associated with HEC1B cells pre-treated 
with anti-CD9 (63 %), anti-CD81 (54 %), anti-CD151 (43 %) and anti-CD63 (35 %) 
antibodies compared to the isotype control cells as shown in Figure 5.3 B. In addition, no 
significant reduction was seen in the number of bacteria per infected cells, compared to 
the isotype control (Figure 5.3 C). 
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Figure 5.3 The effect of anti-tetraspanin antibodies on GFP-labelled P. aeruginosa 
adherence to HEC1B cells.  
HEC1B cells were pre-treated with anti-tetraspanin antibodies (10 μg/ml) or the isotype control 
antibody for 30 minutes. GFP-labelled P. aeruginosa was incubated with adherent cells at MOI 
of 10 for 60 minutes, the cells were fixed, stained, then visualised using fluorescence microscopy 
and the number of infected cells was counted. (A) The percentage of cells with adherent bacteria. 
(B) The change in the number of bacteria per 100 cells. (C) The change in number of bacteria per 
infected cells, calculated as described in section 2.2.4, Results are mean ± standard error of the 
mean (SEM), N= 4. Data were analysed using One-way ANOVA with Sidak’s multiple 
comparisons test (vs. isotype control), *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.00, ns is non-
significant.  
  
  
 
111 
5.2.2 The effect of EC2: GST proteins on GFP-labelled P. aeruginosa adhesion 
to host cells 
Since anti-tetraspanin antibodies had an inhibitory effect on GFP-labelled P. aeruginosa 
infection of the three cell lines investigated, it appeared appropriate here to test the effect 
of the corresponding soluble EC2 proteins. These recombinant proteins were expressed 
as GST-fusion proteins in E. coli and had been prepared by our lab group (Fanaei et al., 
2011).  
In order to study the effect of EC2: GST proteins on GFP-labelled P. aeruginosa. 
adhesion to host cells by immunofluorescent microscopy, the cells were incubated with 
EC2: GST proteins at 500 nM or the glutathione S-transferase (GST) (the protein tag) 
control prior to the introduction of the GFP-labelled P. aeruginosa.  
5.2.2.1 The effect of EC2:GST proteins on GFP-labelled P. aeruginosa adhesion to 
A549 epithelial cells 
The effect of EC2: GST proteins on A549 epithelial cells is presented in Figure 5.4. After 
60 minutes of infection, the percentage of cells associated with bacteria was significantly 
reduced after pre-treatment with EC2-CD9 (68 %), EC2-CD63 (51 %), EC2-CD81 (43 
%) and EC2-CD151(34 %), when compared to the GST control (Figure 5.4 A). However, 
no significant reduction was observed in terms of the number of bacteria associated with 
epithelial cells compared to the GST control cells as shown in Figure 5.4 B. In addition, 
no significant reduction was observed in the number of bacteria per infected cells, 
compared to the GST control (Figure 5.4 C). 
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Figure 5.4 The effect of EC2: GST proteins on GFP-labelled P. aeruginosa 
adherence to A549 cells.  
A549 cells were pre-treated with EC2: GST proteins (500 nM) or the GST control for 30 minutes. 
GFP-labelled P. aeruginosa were incubated with adherent cells at MOI of 10 for 60 minutes, the 
cells were fixed, stained, then visualised using fluorescence microscopy and the number of 
infected cells was counted. (A) The percentage of cells with adherent bacteria. (B) The change in 
the number of bacteria per 100 cells. (C) The change in number of bacteria per infected cells, 
calculated as described in section 2.2.4, Results are mean ± standard error of the mean (SEM), 
N= 4. Data were analysed using One-way ANOVA with Sidak’s multiple comparisons test (vs. 
GST control), *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001, ns is non-significant.  
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5.2.2.2 The effect of EC2:GST proteins on GFP-labelled P. aeruginosa adhesion to 
HaCaT keratinocyte cells 
The effect of EC2: GST proteins on pre-treated HaCaT cells is shown in Figure 5.5. After 
60 minutes of infection, the percentage of cells associated with bacteria was significantly 
reduced after pre-treatment with EC2-CD81 (80 %), EC2-CD9 (75 %), EC2-CD63 (70 
%) and EC2-CD151 (64 %), when compared to the GST control (Figure 5.5 A). 
Moreover, a significant reduction was observed in terms of the number of bacteria 
associated with HaCaT cells pre-treated with EC2-CD9 (69 %), EC2-CD81 (69 %), EC2-
CD63 (56 %) and EC2-CD151 (55 %), compared to the GST control cells as shown in 
Figure 5.5 B. Additionally, no significant reduction was seen in the number of bacteria 
per infected cells, compared to the GST control (Figure 5.5 C). 
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Figure 5.5 The effect of EC2: GST proteins on GFP-labelled P. aeruginosa 
adherence to HaCaT cells.  
HaCaT cells were pre-treated with EC2: GST proteins (500 nM) or the GST control for 30 
minutes. GFP-labelled P. aeruginosa were incubated with adherent cells at MOI of 10 for 60 
minutes, the cells were fixed, stained, then visualised using fluorescence microscopy and the 
number of infected cells was counted. (A) The percentage of cells with adherent bacteria. (B) The 
change in the number of bacteria per 100 cells. (C) The change in number of bacteria per infected 
cells, calculated as described in section 2.2.4, Results are mean ± standard error of the mean 
(SEM), N= 4. Data were analysed using One-way ANOVA with Sidak’s multiple comparisons 
test (vs. GST control), *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001, ****P ≤ 0.0001, ns is non-
significant.  
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5.2.2.3 The effect of EC2:GST proteins on GFP-labelled P. aeruginosa adhesion to 
HEC1B endometrial cells 
The effect of EC2: GST proteins on pre-treated HEC1B cells is displayed in Figure 5.6. 
After 60 minutes of infection, the percentage of cells associated with bacteria was 
significantly reduced after pre-treatment with EC2-CD9 (82 %), EC2-CD81 (70 %), and 
EC2-CD63 (66 %), when compared to the GST control (Figure 5.6 A). However, a 
significant reduction was observed in terms of the number of bacteria associated with 
HEC1B cells pre-treated with EC2-CD9 (51 %) and EC2-CD63 (51 %), compared to the 
GST control cells as presented in Figure 5.6 B. Furthermore, no significant reduction was 
observed in the number of bacteria per infected cells, compared to the GST control 
(Figure 5.6 C). 
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Figure 5.6 The effect of EC2: GST proteins on GFP-labelled P. aeruginosa 
adherence to HEC1B cells.  
HEC1B cells were pre-treated with EC2: GST proteins (500 nM) or the GST control for 30 
minutes. GFP-labelled P. aeruginosa were incubated with adherent cells at MOI of 10 for 60 
minutes, the cells were fixed, stained, then visualised using fluorescence microscopy and the 
number of infected cells was counted. (A) The percentage of cells with adherent bacteria. (B) The 
change in the number of bacteria per 100 cells. (C) The change in number of bacteria per infected 
cells, calculated as described in section 2.2.4, Results are mean ± standard error of the mean 
(SEM), N= 4. Data were analysed using One-way ANOVA with Sidak’s multiple comparisons 
test (vs. GST control), *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001, ns is non-significant.  
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5.2.3 The role of LPS contamination in EC2: GST protein induced adherence 
of GFP-labelled P. aeruginosa to host cells 
A possible reason for the reduction in GFP-labelled P. aeruginosa adherence could be 
due to the downstream effects of the residual lipopolysaccharide (LPS), which is 
contained in the recombinant protein as a contaminant from the protein expression and 
purification process (chapter 2). Fanaei (2013) measured the residual levels of LPS as 
shown in Table 5.1. The experiment revealed that there is no significant effect of LPS on 
the adhesion of GFP-labelled P. aeruginosa to HEC1B cells and that the effect of the 
reduction in adhesion observed in the cells pre-treated with recombinant proteins is not 
due to LPS contamination (Figure 5.7). 
 
Table 5.1: The LPS content of recombinant proteins (ng/ml) per 500 nM protein 
solution. 
 
Recombinant Protein LPS content (ng /ml in 500nM protein solution) 
GST (Rosetta Gami) 3.25 
CD9 EC2: GST (Rosetta 
Gami) 
12.40 
Data obtained by a previous student in our lab group (Fanaei, 2013) using the Limulus 
Ameobocyte Lysate chromogenic assay. 
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Figure 5.7 The effect of LPS on the adhesion of GFP-labelled P. aeruginosa to 
HEC1B cells.  
HEC1B cells were pre-treated with a range of concentrations of LPS for 30 minutes. CD9 EC2: 
GST protein was used as a positive control. GFP-labelled P. aeruginosa were incubated with 
adherent cells for 60 minutes at an MOI of 10, the cells were then fixed, stained, then visualised 
by fluorescent microscopy. (A) The percentage of infected cells. (B) The percentage of number 
of bacteria per 100 cells. Data were normalised to the GST control cells. Results are mean ± 
standard error of the mean (SEM), N= 4. Data were analysed using One-way ANOVA with 
Sidak’s multiple comparisons test (vs. GST control), **P ≤ 0.01 and ****P ≤ 0.0001, ns is non-
significant.  
 
 
 
 
  
  
 
119 
5.2.4 Anti-tetraspanin antibodies protect A549 and HEC1B cells from P. 
aeruginosa mediated toxicity 
Anti-tetraspanin antibodies were examined for their ability to protect A549 and HEC1B 
cells against P. aeruginosa-induced cytotoxicity. The level of LDH activity post-infection 
of human cells was determined. Briefly, A549 and HEC1B cells were seeded in a 96-well 
plate (10,000 cells/well in 100 μl complete media) and allowed to attach at 37°C, 5 % 
CO2 for 16 hours to achieve a 70-80 % confluent monolayer. The confluent cells were 
incubated with 10 μg/ml of anti-CD9 and anti-CD81 anti-tetraspanin antibodies for 30 
minutes before the infection with P. aeruginosa at MOI of 10 for 16 hours, as described 
in section 2.2.8. 
Following treatment with anti-CD9 and CD81 antibodies, the level of LDH released from 
A549 cells decreased to 40 % and 52 % respectively, these levels were significantly lower 
compared to the untreated infected cells (121 %) as shown in Figure 5.8 A. Similarly, 
treatment of HECB1 cells with the same antibodies decreased the level of LDH released 
to 9.3 % and 31 % respectively, compared to untreated infected cells (116 %) as shown 
in Figure 5.8 B.  
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Figure 5.8 The effect of anti-tetraspanin antibodies treatment on A549 and HEC1B 
cell lines.  
Monolayers of A549 (A) and HEC1B cells (B) were exposed to anti-CD9 and anti-CD81 
antibodies at 10 μg/ml at 37°C, 5 % CO2 for 30 minutes. Cytotoxicity was assessed by measuring 
the level of LDH released and expressed as a % of total LDH obtained from the control cell lysate 
(treated with Trito  n X-100). Results are mean ± standard error of the mean (SEM), N= 4. Data 
were analysed using One-way ANOVA with Sidak’s multiple comparisons test (vs. infected 
cells), **P ≤ 0.01 and ****P ≤ 0.0001.  
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5.3 Discussion 
Here we have shown that pre-treatment of three different cell lines (A549, HaCaT and 
HEC1B) with certain reagents (anti-tetraspanin antibodies and EC2: GST recombinant 
proteins) significantly reduces GFP-labelled P. aeruginosa adhesion. In addition, this effect 
is not due to LPS contamination in the protein. Moreover, anti-CD9 and anti-CD81 
protect human cells against P. aeruginosa -induced cytotoxicity. 
This study found that the recombinant tetraspanin EC2: GST proteins affected the 
adherence of P. aeruginosa to a higher degree than the antibody treatment, in all the cell 
lines used. This is in agreement with a previous study which found that the EC2 fusion 
proteins were able to reduce the adherence of N. meningitidis to a higher degree than the 
interference of tetraspanins with antibodies (Green et al., 2011b). In addition, anti-
tetraspanin antibodies and EC2: GST proteins have been shown to be effective at 
decreasing the adhesion of several Gram negative and Gram positive bacteria to epithelial 
cells (Green et al., 2011b). It seems that tetraspanins are involved in the adhesion of 
numerous bacteria to the host, including environmental strains such as E. coli and 
pathogenic such as Staphylococcus and Pseudomonas. This similar effect in different 
types of bacteria suggests that the tetraspanins have a general role in bacterial adhesion, 
rather than acting as specific receptors. There is an interaction with partner proteins on 
the cell membrane such as integrins, through TEM, and, TEMs act as adhesion platforms 
used by the bacteria to associate with the host cell. Our group has proposed that using 
tetraspanin proteins may disrupt TEM order in the cell membrane (Jennifer Wood, MSc 
dissertation, 2017) which results in clustering or changing of bacterial receptor on the 
host cell. However, the actual mechanism of action of these proteins has not been 
explained.  
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TEMs potentially contain receptors that the bacteria can use to bind to a host cell, by 
clustering these receptors that act as ‘adhesion platforms’ the bacteria will no longer 
recognise their receptor which will subsequently result in reducing the attachment to the 
cell membrane. This may explain the reduction in bacterial adhesion seen in this study. 
Additionally, the role of LPS contamination in EC2 protein induced adherence of 
Pseudomonas to HEC1B cells was investigated. LPS is one of the major components of 
the cell wall of Gram-negative bacteria, it is a toxin that can affect many cellular processes 
in a human cell (Bausinger et al., 2002; Wakelin et al., 2006). It has been shown that a 
high dose of LPS may cause multiple organs failure and septic shock (Alexander and 
Rietschel, 2001). Therefore, it is important to investigate the possible effects of this 
Gram-negative endotoxin on bacterial interactions with host cells. HEC1B cells have 
been reported to express Toll-like receptor 4 (TLR4) (Aboussahoud et al., 2010). TLR4 
may bind LPS and stimulate many immune cellular responses, such as cytokine and 
chemokine production (Medzhitov and Janeway, 2002). The existence of these molecules 
is able to severely change the interaction between the pathogen and the host cell. LPS 
also contributes to Gram-negative bacterial colonisation through hydrogen bonding on 
the surface of human cells (Sheng et al., 2008). As LPS contamination was unavoidable 
during the production and purification of the EC2: GST recombinant proteins (used in 
this study) (Petsch and Anspach, 2000), it was important to assess that the reduction in 
adhesion seen in the cells pre-treated with recombinant proteins is not due to LPS 
contamination. The data presented in Figure 5.7 shows that there was no obvious effect 
of LPS on the interaction between HEC1B cells and P. aeruginosa at concentrations 
significantly higher than the levels found as contamination in the EC2: GST recombinant 
proteins. Taken together, this provides evidence that the contamination is not causative 
to the phenomenon being examined.  
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In summary, the ability of recombinant human tetraspanin EC2: GST proteins and anti 
tetraspanin antibodies to inhibit the adhesion of GFP-labelled P. aeruginosa to three cell 
lines has been demonstrated. There is evidence that this effect is not due to LPS 
contamination, therefore it can be deduced that LPS existing in the recombinant protein 
samples did not contribute to the reduction in the numbers of P. aeruginosa adhering to 
host cells. Moreover, it is hypothesised that by intercalating into the tetraspanin web, the 
TEMs may disrupt the ‘adhesion platforms’ which may reduce the bacterial binding to 
the host cell receptor. Interestingly, when the efficacy of the tetraspanin treatments 
against GFP-labelled P. aeruginosa adherence is correlated with tetraspanin expression 
on the cell surface, as quantified by flow cytometry in chapter 3 we can see a direct 
correlation between the two parameters. In this study CD9 and CD81 were found to be 
expressed at high levels in A549, HaCaT and HEC1B cells, and they seem to have a direct 
role in GFP-labelled P. aeruginosa adherence, because the pre-treatment with anti-CD9 
and anti-CD81 antibodies as well as EC2 proteins of CD9 and CD81 significantly reduced 
GFP-labelled P. aeruginosa adhesion. In addition, CD151 was found to have high 
expression level in A549 and HaCaT cells, and the pre-treatment with anti-CD151 and 
EC2 protein of CD151 reduced GFP-labelled P. aeruginosa adhesion. Furthermore, 
CD151 was expressed at very low level in HEC1B cells, and the pre-treatment with anti-
CD151 and EC2 protein of CD151 had no effect in bacterial adhesion to this cell line. 
Finally, anti-CD9 and anti-CD81 protect A549 and HEC1B cells from P. aeruginosa-
induced cytotoxicity and that because they have an effect to in reducing GFP-labelled P. 
aeruginosa adhesion . The next chapter will investigate the role of peptide fragments 
derived from CD9 EC2 protein in reducing the adhesion and internalisation of GFP-
labelled P. aeruginosa into host cells. 
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CHAPTER 6: The effect of CD9 EC2-derived 
peptides on GFP-labelled P. aeruginosa 
adherence to human cells
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6.1 Introduction 
In the work described in chapter 5, we investigated the role of tetraspanins in GFP-
labelled P. aeruginosa attachment to epithelial cells. There was a significant reduction in 
adhesion when the host cells were incubated with the recombinant CD9 EC2 protein or 
anti-CD9 antibody. Similarly, previous studies have demonstrated the ability of CD9 EC2 
proteins to reduce the adherence of various strains of both Gram-positive and Gram-
negative bacteria to human epithelial cell lines (Hassuna et al., 2009; Green et al., 2011a; 
Ventress et al., 2016). Pre-treatment of human keratinocytes like HaCaT cells with low 
nanomolar concentrations of some CD9 EC2-derived peptides followed by infection with 
different S. aureus strains has been reported to significantly reduce bacterial adhesion 
(Ventress, Partridge et al., 2016). Therefore, in this chapter, an attempt was made to 
investigate the efficacy in reducing bacterial adhesion of eight peptides derived from the 
primary sequence of the tetraspanin CD9 EC2 domain (Figure 6.1). Furthermore, the 
possible cytotoxicity of the peptides on A549 cells and GFP-labelled P. aeruginosa was 
investigated. Finally, the effect of peptide 810 on the secretion of pro-inflammatory 
cytokines IL-6 and IL-8 was assessed. 
6.1.1 Tetraspanin CD9 peptide fragments  
CD9 EC2-derived peptides were developed based on the amino acid sequence of the 
EC2 region of CD9 (Tetraspanin 29) as shown in Figure 6.1 and Figure 6.2. Also, for 
each peptide a scrambled peptide control was designed with a randomised sequence of 
the amino acids (sequences in section 2.9.1.2). 
 
 
  
 
126 
 
Figure 6.1 CD9 EC2-derived peptides corresponding to different regions of 
CD9EC2. 
The amino acid sequence of (A) peptides 800, 810, 8001, 8002, 8003 and 8004. (B) peptide 8005 
and (C) peptide 800-Cap, diagram generated by Dr Cozens.  
 
 
 
Figure 6.2 Tetraspanin CD9 structure. 
The EC2 extracellular domain of the CD9 sequence shows the locations of the eight peptides, 
helices are shown in red and loops in green. The second image ('180') is rotated by 180 degrees 
(predicted CD9 EC2 structure using PyMOl by Dr.Issa). 
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Figure 6.3 The peptide fragments from CD9 EC2. 
The location of each peptide on the CD9 EC2 is shown in white. Other helices are shown in red and loops in green. The second image ('180') is rotated by 180 
degrees, diagram generated by Dr Issa.
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The aims of this chapter: 
 
• To determine the effects of peptides on GFP-labelled P. aeruginosa growth 
and viability using the BacTiter-GloTM Assay. 
• To investigate the effect of CD9 EC2-derived peptides (800, 810, 8001, 8002, 
8003, 8004, 8005 and 800-Cap) on GFP-labelled P. aeruginosa adhesion to 
three human cell lines (A549 cells, HaCaT cells and HEC1B cells). 
• To determine the dose-response of the most effective peptides. 
• To investigate the effect of peptides 800, 810 and 8003 on GFP-labelled P. 
aeruginosa internalisation using a gentamicin protection assay. 
• To assess the A549 cells viability using MTT assay. 
• To determine the production of cytokines in cells treated with peptide 810 
using CBA. 
6.2 Results 
6.2.1 The effects of CD9 EC2-derived peptides on GFP-labelled P. aeruginosa 
growth and viability 
ATP is a direct measure of the metabolic activity in the cell and can be measured by 
quantifying the light constructed in a reaction with the naturally-occurring firefly enzyme 
Luciferase using a Luminometer. The quantity of light generated is directly proportional 
to the quantity of biological energy present in the cells. Therefore, to investigate the 
possible toxic effects of CD9 EC2-derived peptides on GFP-labelled P. aeruginosa, an 
ATP assay was performed to measure the metabolic activity (section 2.2.10.1). A linear 
correlation between rATP concentration and luminescence was obtained (rΛ2=0.9856) 
y=9E+X0.7401, where y represents the luminescence in RLU and x represents ATP 
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concentration in μM. This was used to determine the ATP concentration based on 
luminescence.   
The rate of proliferation of GFP-labelled P. aeruginosa was monitored (section 2.2.2.2) 
in order to identify the characteristic phases of growth (Figure 6.4). The lag phase, the 
first stage where the bacterial cells are adjusting to the new media, was almost absent 
under the investigated experimental conditions. This is maybe because LB medium was 
used to prepare both the inoculum culture and sub-population culture. The log 
(exponential) phase was identified between 30 minutes and 6 hours, where GFP-labelled 
P. aeruginosa achieved the maximum rate of growth. GFP-labelled P. aeruginosa 
reached the mid-exponential phase within 2 to 3 hours of incubation, an OD600 of ~0.5 
which was determined by calculating the average optical density between the start and 
endpoint of the log phase. Switch from the late-exponential (OD600 of 1.0) to the early-
stationary phase (OD600 of 1.2) was displayed between 6 and 8 hours, respectively. The 
rate of proliferation was thereafter unchanged, with GFP-labelled P. aeruginosa cultures 
reaching the stationary phase of growth by 18 hours.  
GFP-labelled P. aeruginosa cultures were treated with different peptides and scrambled 
control peptides (200 nM) during the log phase of growth and ATP production was 
monitored for 4 hours. The ATP production in GFP-labelled P. aeruginosa after treatment 
with peptides was measured in comparison to the control (untreated bacteria). Within 4 
hours, the ATP concentration appeared to increase in the GFP-labelled P. aeruginosa 
(untreated) from 111 nM to 209 nM and in the GFP-labelled P. aeruginosa treated with 
all CD9 EC2-derived peptides, and the scrambled control peptides followed a similar 
increasing pattern which indicated that these peptides and the corresponding scrambled 
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control peptides were not toxic to the viability of GFP-labelled P. aeruginosa (Figure 
6.5). 
 
 
 
Figure 6.4 Growth curve of GFP-labelled P. aeruginosa over time in LB medium.   
Overnight cultures of GFP-labelled P. aeruginosa were diluted to an OD600 of 0.05 and grown in 
LB at 37°C for 24 hours, with agitation at 120 rpm. OD was measured at 600 nm, N= 3. 
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Figure 6.5 Quantification of ATP production in the GFP-labelled P. aeruginosa post-
exposure to CD9 EC2-derived peptides.  
Cultures of GFP-labelled P. aeruginosa were grown in LB in the presence of different CD9 EC2-
derived peptides and scrambled control peptides (200 nM) for 4 hours at 37oC, with agitation at 
120 rpm. ATP production was quantified using the BacTiter-GloTM Assay (Promega, UK). 
Readings were taken at 0, 2 and 4 hours after addition of the CD9 EC2-dervied peptides or 
scrambled control peptides. The data were analysed using Two-way ANOVA (vs. untreated P. 
aeruginosa), N= 4. Result are mean standard error of the mean (SEM). 
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6.2.2 The effect of CD9 EC2-derived peptides on GFP-labelled P. aeruginosa 
adherence to human cells 
6.2.2.1 The effect of CD9 EC2-derived peptides on GFP-labelled P. aeruginosa 
adherence to A549 epithelial cells 
To determine the effects of CD9 EC2-derived peptides on bacterial adherence, A549 cells 
were pre-treated with CD9 EC2-derived peptides and their corresponding scrambled 
control peptides at 200 nM (Figure 6.6 A) or 20 nM (Figure 6.6 B) followed by infection 
for one hour with GFP-labelled P. aeruginosa (section 2.2.4). All CD9 EC2-derived 
peptides used at 200 nM and 20 nM significantly decreased the binding of GFP-labelled 
P. aeruginosa to A549 cells when compared with the untreated cells. At 200 nM, the 
scrambled control peptides produced a significant reduction in GFP-labelled P. 
aeruginosa adhesion to A549 cells when compared with the untreated cells, however the 
scrambled control peptides used at 20 nM had no effect when compared with the untreated 
cells. Therefore, the CD9 EC2-derived peptides and their corresponding scrambled 
control peptides were used at a concentration of 20 nM in the further investigations.  
6.2.2.2 The effect of CD9-derived peptides on GFP-labelled P. aeruginosa adherence 
to HaCaT keratinocyte cells 
HaCaT cells pre-treated with all CD9 EC2-derived peptides at 200 nM (Figure 6.7 A) or 
20 nM (Figure 6.7 B) significantly reduced the binding of GFP-labelled P. aeruginosa to 
HaCaT cells when compared with the untreated cells. Additionally, the scrambled control 
peptides had no significant effect on the binding of GFP-labelled P. aeruginosa to HaCaT 
cells at 200 nM and 20 nM when compared with the untreated cells. 
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6.2.2.3 The effect of CD9-derived peptides on GFP-labelled P. aeruginosa adherence 
to HEC1B endometrial cells 
All CD9 EC2-derived peptides and their corresponding scrambled control peptides used 
at 200 nM significantly reduced the GFP-labelled P. aeruginosa adhesion to HEC1B cells 
when compared with the untreated cells (Figure 6.8 A). However, the lower concentration 
of the peptides showed specific effects; HEC1B cells pre-treated with peptides 800, 810, 
8001, 8003, 8005 and 800-Cap at 20 nM significantly reduced the binding of GFP-
labelled P. aeruginosa when compared to the untreated cells. While the pre-treatment 
with peptides 8002 and 8004 at 20 nM had no effect on the binding profile of GFP-
labelled P. aeruginosa to HEC1B cells when compared with the untreated cells. 
Additionally, no effect was observed for all the scrambled control peptides used at 20 
nM, when compared with the untreated cells (Figure 6.8 B).  
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Figure 6.6 Effect of CD9 EC2-derived peptides on GFP-labelled P. aeruginosa 
adherence to A549 cells.  
A549 cells were treated with CD9 EC2-derived peptides and their corresponding scrambled 
control peptides at (A) 200 nM or (B) 20 nM for 30 minutes. The adherent cells were washed and 
then infected with GFP-labelled P. aeruginosa for 60 minutes at an MOI of 10. A549 cells were 
fixed, stained, then visualised using fluorescent microscopy. The percentage of infected cells was 
normalised to the untreated control infected cells (100 cells). Results are mean ± standard error 
of the mean (SEM), N= 4. Data were analysed using One-way ANOVA with Sidak post-test 
(vs.the scrambled control peptides), ****P ≤ 0.0001, ***P ≤ 0.001.  
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Figure 6.7 Effect of CD9 EC2-derived peptides on GFP-labelled P. aeruginosa 
adherence to HaCaT cells.  
HaCaT cells were treated with CD9 EC2-derived peptides and their corresponding scrambled 
control peptides at (A) 200 nM or (B) 20 nM for 30 minutes. The adherent cells were washed and 
then infected with GFP-labelled P. aeruginosa for 60 minutes at an MOI of 10. HaCaT cells were 
fixed, stained, then visualised using fluorescent microscopy. The percentage of infected cells was 
normalised to the untreated control infected cells (100 cells). Results are mean ± standard error 
of the mean (SEM), N= 4. Data were analysed using One-way ANOVA with Sidak post-test 
(vs.the scrambled control peptides), ****P ≤ 0.0001, ***P ≤ 0.001.
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Figure 6.8 Effect of CD9 EC2-derived peptides on GFP-labelled P. aeruginosa 
adherence to HEC1B cells.  
HEC1B cells were treated with CD9 EC2-derived peptides and their corresponding scrambled 
control peptides at (A) 200 nM or (B) 20 nM for 30 minutes. The adherent cells were washed and 
then infected with GFP-labelled P. aeruginosa for 60 minutes at an MOI of 10. HEC1B cells were 
fixed, stained, then visualised using fluorescent microscopy. The percentage of infected cells was 
normalised to the untreated control infected cells (100 cells). Results are mean ± standard error 
of the mean (SEM), N= 4. Data were analysed using One-way ANOVA with Sidak post-test (vs. 
the scrambled control peptides), ****P ≤ 0.0001, ***P ≤ 0.001 and ns is non-significant.  
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6.2.3 The optimum dose for CD9 EC2-derived peptides 810, 8003 and 800-
Cap on GFP-labelled P. aeruginosa adherence to A549 cells 
As observed from the previous results (section 6.3.2.1), the most effective peptides to 
reduce GFP-labelled P. aeruginosa adherence to A549 cells were the 810, 8003 and 800-
Cap peptides. Thus, the effect of these CD9 EC2-derived peptides in GFP-labelled P. 
aeruginosa adherence to A549 cells was investigated by producing dose response curves 
to determine the concentration that inhibits 50 % of bacterial adhesion (IC50). In this 
experiment, A549 cells were pre-treated with different concentrations of the peptides 
ranging from 0.3 nM to 20 nM for 30 minutes after which they were infected with GFP-
labelled P. aeruginosa for 60 minutes at MOI of 10. The cells were fixed and counted 
manually under a fluorescent microscope and analysed using a three parameters nonlinear 
regression. These peptides were capable of significantly reducing the percentage of 
infected cells (Figure 6.9). The results show that peptide 810 had an IC50 of 2.4 nM 
(Figure 6.8 A), whereas peptide 8003 had an IC50 of 3.4 nM (Figure 6.8 B) and peptide 
800-Cap had an IC50 of 3.2 nM (Figure 6.8 C). Thus, peptide 810 presented the most 
effective inhibition of GFP-labelled P. aeruginosa adhesion to A549 cells. 
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Figure 6.9 Dose-response curves of CD9 EC2-derived peptides 810, 8003 and 800-
Cap in A549 cells infected with GFP-labelled P. aeruginosa.   
A549 cells were pre-treated with CD9 EC2-derived peptides over a range of concentrations, from 
0.3 nM to 20 nM for 30 minutes. The adherent cells were washed and subsequently infected with 
GFP-labelled P. aeruginosa for 60 minutes at an MOI of 10. A549 cells were fixed and DAPI 
stained, allowing for analysis of adherence using fluorescent microscopy (section 2.2.4). Samples 
were calculated as a percentage against a control of untreated cells, which was normalised 100 
%.  X scale plotted as power of 10. Line represents log (inhibitor) vs. response (three parameters). 
Result are mean ± standard error of the mean (SEM). The R square for peptide 810 is 0.891, for 
peptide 8003 is 0.918 and for peptide 800-Cap is 0.906, N= 4.  
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6.2.4 The effect of CD9 EC2-derived peptides on P. aeruginosa internalisation 
into A549 epithelial cells 
CD9 EC2-derived peptides were tested on A549 cells for their ability to reduce 
internalisation of GFP-labelled P. aeruginosa. Alveolar epithelial (A549) cells were 
chosen because they are an established model for the study of Pseudomonas 
internalisation (Hawdon et al., 2010). 
6.2.4.1 Determination of the optimal (MOI) 
In order to investigate the effects of CD9 EC2-derived peptides on GFP-labelled P. 
aeruginosa internalisation into A549 cells, a range of MOIs (1, 10 and 50) were tested to 
determine the optimal MOI, using an antibiotic exclusion assay (section 2.2.9.1). The 
results showed that the percentage of internalised bacteria for MOI of 1 was 5 %, MOI of 
10 was 8 % and MOI of 50 was 7 %.  MOI of 10 was chosen as there was no statistically 
significant difference vs MOI of 50 and MOI of 1 gave a lower percentage of internalised 
bacteria (Figure 6.10 A). 
 6.2.4.2 The effect of CD9 EC2-derived peptides on GFP-labelled P. aeruginosa 
internalisation into A549 cells 
As mentioned in section 6.2.2.1 peptides 800, 8003 and 810 reduced the adherence of 
GFP-labelled P. aeruginosa to A549 cell by 40 %, 30 % and 23 %, respectively, at MOI 
of 10. The ability of these peptides to reduce the internalisation of GFP-labelled P. 
aeruginosa into A549 cells was assessed using an antibiotic exclusion assay. The results 
showed that there was no significant difference in bacterial internalisation post-treatment 
with the peptides and also with the corresponding scrambled control peptides, when 
compared to the untreated cells. Surprisingly, A549 cells pre-treated with the scrambled 
  
 
140 
control peptide 800 reduced the percentage of internalised GFP-labelled P. aeruginosa 
by only 2 %, when compared to the untreated cells, while peptide 800 reduced by only 3 
%.  Additionally, peptides 810 and 8003 together with the corresponding control peptides 
exhibited a similar reduction in the percentage of internalised bacteria, when compared 
to the untreated cells. However, for all the tested peptides and their corresponding control 
peptides the difference was not statistically significant when compared to the untreated 
cells (Figure 6.10 B).  
 
 
 
 
Figure 6.10 Internalisation of GFP-labelled P. aeruginosa into A549 cells. 
(A) A549 cells were seeded in 6 well plates at 37°C, 5 % CO2 for 48 hours. Cells were washed 
before being infected with GFP-labelled P. aeruginosa at a range of MOIs (1, 10 and 50) at 37°C 
for 60 minutes, this was followed by washing, and then 1 ml of gentamicin was added at 37°C for 
60 minutes to kill extracellular bacteria. A549 cells were washed before adding 1 ml of lysis 
buffer for 20 minutes, after incubation A549 cells were washed and a cell scraper was used to 
detached the cells. Aliquots of 100l were then spread onto LB plates. Agar plates were incubated 
at 37°C for 24 hours before the bacterial colonies were enumerated and expressed as percentage 
of input bacteria, N= 4. (B) MOI of 10 was used to infect the cells after the peptides and scrambled 
control peptides treatment for 30 minutes. Result are mean ± standard error of the mean (SEM). 
Data were analysed using One-way ANOVA (vs. untreated cells), ns is non-significant, N=4. 
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6.2.5 The cytotoxic effect of CD9 EC2-derived peptides on A549 cells 
The viability of A549 cells was determined in the context of the percentage of MTT 
metabolised by untreated cells to quantitatively assess the effects of CD9 EC2-derived 
peptides at 500 nM on A549 cells. Briefly, A549 cells were seeded in a 96-well plate 
(10,000 cells/well in 100 μl complete media) and allowed to attach at 37°C, 5 % CO2 for 
16 hours to achieve a 70-80 % confluent monolayer. A549 cells were then incubated with 
CD9 EC2-derived peptides for 30 minutes before the infection with P. aeruginosa with 
MOI of 10 for 16 hours, section 2.2.10.2.  
The percentage of viable A549 cells after exposure to CD9 EC2-derived peptides was not 
significantly different compared to the control (untreated cells), but significantly higher 
compared to the cells treated with Triton
 
X-100. The results indicate that the 
concentration of 500 nM did not cause a significant loss in mitochondrial function, as 
indicated by the high cell viability measurements. This concentration was therefore 
considered non-cytotoxic to A549 cells under these conditions (Figure 6.11).  
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Figure 6.11 Viability of A549 cells following exposure to CD9 EC2-derived peptides. 
A549 cells were incubated with 500 nM of CD9 EC2-derived peptides for 30 minutes at 37°C, 5 
% CO2. Viability was assessed using the MTT assay and expressed relative to the untreated 
control cells (100 %). Results are mean ± standard error of the mean (SEM). Data were analysed 
using One-way ANOVA with Dunnett test (vs. untreated cells), ****P ≤ 0.0001 and ns is non-
significant, N= 4. 
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6.2.6 The effect of peptide 810 on cytokine release from A549 and HEC1B 
cells 
Having established that peptide 810 effectively reduced bacterial adhesion to the A549 
cells and HEC1B cell lines (chapter 6), it was decided to measure cytokine release to 
determine if the loss of adhesion also affected the immune response. The cytokines 
released by A549 and HEC1B cells pre-treated with peptide 810, and then infected with 
GFP-labelled P. aeruginosa were investigated (section 2.2.7). Initial experiments were 
undertaken to establish the optimal time for the highest cytokine release from peptide 810 
treated and infected cells (Appendix 1). 
Figure 6.12 A shows the level of IL-8 secreted by A549 cells pre-treated with peptide 810 
and infected with GFP-labelled P. aeruginosa at MOI of 35 (this MOI was determined 
from previous flow cytometry optimisation expirements). The results show that there was 
a significant increase (by 32%) in the level of IL-8 released when compared with the 
untreated cells. Moreover, cells pre-treated with the scrambled control had no significant 
difference in the cytokine release, P > 0.9 vs untreated. Additionally, the level of IL-6 
released was not significantly different when comparing the peptide 810-treated A549 
cells and scrambled control vs untreated cells, Figure 6.12 B. However, the levels of the 
two cytokines IL-8 and IL-6 were not significantly different for HEC1B cell pre-treated 
with peptide 810 or scrambled control peptide when compared to the untreated cells 
(Figure 6.12 C and D). 
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Figure 6.12 The effect of peptide 810 on IL-6 and IL-8 release from A549 and 
HEC1B cells following infection with GFP-labelled P. aeruginosa. 
The supernatants from peptide treated cells that were then infected with GFP-labelled P. 
aeruginosa were collected after 18 hours of incubation at 37°C, 5 % CO2 for analysis using CBA. 
Results are mean ± standard error of the mean (SEM), N= 3. Data were analysed using One-way 
ANOVA with Bonferroni’s multiple comparisons test (vs. untreated cells), *P ≤ 0.05 and ns is 
non-significant. 
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6.3 Discussion 
From a therapeutic point-of-view, tetraspanin based anti-adherence peptides display low 
toxicity towards human cells and the pathogen, which makes them promising candidates 
for anti-bacterial therapy (Ventress et al., 2016). There is no evidence yet of the exact 
mechanism of action for tetraspanins peptides, but they are thought to work in a similarly 
way to the tetraspanin EC2 domains or antibodies (discussed in chapter 4), perhaps by 
interpolating into TEMs on the cell membrane. This could lead to disruption of the 
proteins through protein interactions and disordering of the TEMs. This would affect 
bacterial adhesin molecule interactions with TEM and thus reduce adhesion. 
In this study, we demonstrate that pre-treatment of three cell lines with short (≤ 50 amino 
acid) peptides directly derived from the sequence of the EC2 domain of tetraspanin CD9 
significantly reduced the adherence of GFP-labelled P. aeruginosa, but not 
internalisation. This study also found that in the three cell lines tested, the peptides were 
not toxic towards the bacteria. In addition, no significant effects were seen on human cell 
metabolism, indicating that this may be a promising drug in an anti-adhesive therapy 
against bacterial infection. Finally, a slight increase was observed in the release of 
cytokine IL-8 after A549 cells were pre-treated with peptide 810. 
Previous work from our lab has shown that these peptides are capable of reducing Gram-
negative and Gram-positive bacteria adhesion to host cells (Green et al., 2011a). Cozens 
(2015) demonstrated that six peptides from the sequence of EC2 domain of CD9 were 
able to reduce up to 50 % of meningococcal adhesion to human epithelial cells. 
Furthermore, Ventress et al., (2016) provided some evidence for the potential of using 
these peptides as inhibitors of S. aureus adherence to keratinocytes. Pre-treatment of 
human keratinocytes like HaCaT cells or primary human keratinocytes with 50 nM of 
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peptides 810, 8001 or 800, followed by infection with different strains of S. aureus 
including SH1000, S235 or JE2 MRSA, resulted in a significant reduction in bacterial 
adherence. Peptide 810 was most effective against HaCaT cells infected with the S235 
strain, causing 60 % in bacterial adherence. Recent work by Issa (2017) (unpublished 
data) found that some peptides including 8005 and 800-Cap are very effective in reducing 
the adherence of S. aureus (SH1000) to HaCaT cells. Correspondingly, in this study, pre-
treatment of the tested cell lines with CD9 EC2-derived peptides significantly reduced 
the adherence of GFP-labelled P. aeruginosa by more than 80 % to A549 and HaCaT 
cells, and 37 % to HEC1B cells. This is consistent with the expression level of CD9 in 
the different cell lines as discussed previously in chapter 4, suggesting that the peptides 
may have been affected by the amount of TEMs on the cell surface of different cell types 
when inhibiting bacterial adhesion.  
Previous studies in our lab have shown that scrambled peptides at low concentration have 
no effect on the attachment of various pathogens to host cells. In agreement with this 
study were the scrambled control peptides had no effect at 20 nM, this indicates that the 
anti-adhesive effect is tetraspanin specific and not a non-specific peptide effect (Cozens, 
2015; Ventress, 2016). In this study, the pre-treatment with scrambled control peptides at 
200 nM has been shown to have an effect on Pseudomonas adhesion to host cells 
compared to the untreated cells (control) and this could be due to non-specific activity. 
Work in our lab has shown that some scrambled control peptides e.g. 800-Cap, are 
hydrophobic, with strong affinity to plastic. Moreover, structural analysis of other 
scrambled control peptides e.g 8005, using circular dichroism, has shown that the ∝-
helical confirmation is maintained despite the change in sequence (Dr. Issa, Department 
of Infection and immunity and cardiovascular, University of Sheffield, personal 
communication). This suggests that the activity of peptides depends on both amino acid 
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sequence and helical structure. 
The dose-response experiments to ascertain inhibitory concentration (IC50) values have 
shown differences between peptides, host cells and the bacteria used. In this study, 
peptides showed efficiency at very low concentration (2.4 nM for peptide 810) towards 
the GFP-labelled P. aeruginosa, which was in agreement with previous studies which 
have shown that peptide 8001 and peptide 8003 exhibit low IC50 (4.06 nM and 3.72 nM 
respectively) towards N. meningitidis (Cozens et al., 2016), and even 1 nM of peptide 
800 has been reported efficinet towards S. aureus (Ventress et al., 2016). This difference 
in IC50 values could be due to virulence factors amongst different bacterial types, 
suggesting that the adhesion molecules for the bacterial pathogen may play a role in this 
process. Many Gram-negative and Gram-positive bacteria such as N. gonorrhoea and S. 
aureus express two major adhesin proteins, the type IV pili (Tfp) and phase-variable 
opacity-associated (opa), which promote adherence to epithelial cells (Carbonnelle et al., 
2005). It has been found that a reduction in Neisseria adhesion to cells treated with 
tetraspanin CD9 peptides is related to tfp expression. In contrast, expression of the major 
adhesion protein (opa) in Neisseria (Virji et al., 1996) had no significant effect on 
bacterial adhesion to cells treated with tetraspanin-based peptides (Cozens, 2015). This 
suggests the hypothesis that TEMs play a role as “adhesion platforms” that cluster cell 
membrane protein and aid some bacterial/host cell interactions. 
As mentioned previously, peptides 800, 8003 and 810 were tested to identify their abilities 
to inhibit the adhesion and internalisation of GFP-labelled P. aeruginosa into A549 cells 
after gentamicin treatment, and no effect was observed. In the untreated control cells, 
only 5 bacteria /10000 cells were internalised. This finding is in agreement with previous 
studies that investigated multiple anti-adhesive peptides, and on different epithelial cell 
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line with only about 1-2 % bacteria invading epithelial cell line (Issa, personal 
communication 2016). However, the frequencies of invasion in epithelial cell lines are 
considerably different. Therefore, invasion characteristics cannot always be compared 
across cell lines or bacterial species.  
Furthermore, there was no toxic effect on GFP-labelled P. aeruginosa growth and 
viability during incubation with CD9 EC2-derived peptides, demonstrating that the 
reduction in the number of adherent bacteria is not due to bacteriostatic or bactericidal 
effects. These peptides are therefore unlikely to produce resistant bacteria.  
In summary, peptides based on the EC2 domain of the tetraspanin CD9 have been 
established as effective inhibitors of GFP-labelled P. aeruginosa adherence to human 
cells, but not internalisation. The concentration used was lower than that used for whole 
CD9 EC2 domains, with variations between the IC50 of the peptides. It has been shown 
that these peptides are not toxic to GFP-labelled P. aeruginosa. Moreover, there was no 
significant effect on cell viability after CD9 EC2-derived peptides treatment on A549 
cells, indicating that they could be a valuable addition to present treatments for bacterial 
infection. Finally, the level of cytokines released were measured after treatments with 
peptide 810 and no significant effects were seen. Treatment with these peptides will 
therefore not elicit an immune response.  
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CHAPTER 7: General Discussion 
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7.1 Summary 
In this thesis, we have investigated the action of tetraspanin antibodies, recombinant EC2 
proteins and CD9 EC2-derived peptides on the adhesion of GFP-labelled P. aeruginosa 
to host cells. We hypothesised that tetraspanins may mediate adhesion platform formation 
on the plasma membrane by TEM and form an important mechanism of bacterial adhesion 
to the host cell. 
P. aeruginosa is an opportunistic pathogen, which causes infections in 
immunocompromised individuals, in chronic leg ulcers, burn wounds, pneumonia and the 
lungs of cystic fibrosis patients (Fothergill et al., 2012; Morita et al., 2014; Savoia, 2014). 
P. aeruginosa is notorious for its antibiotic resistance and has been implicated in 
nosocomial infections (Breidenstein et al., 2011). Therefore, developing effective 
antimicrobial agents against multi-drug resistant bacteria is a growing concern in the 
medical community (Kang et al., 2012; Bjarnsholt et al., 2013). Most antimicrobials 
available for treating P. aeruginosa infections directly kill or inhibit the bacterial growth, 
subsequently causing the growth of resistant strains through genetic changes 
(Breidenstein et al., 2011; Morita et al., 2014). Most antimicrobial peptides have less 
specific mechanisms of action (e.g. membrane damage), and a variety of targets, which 
decreases the development of resistance by the pathogen (Jorge et al., 2012). 
One effective method is to target bacterial adherence (Cozens and Read, 2012), as this 
method of treatment should develop less resistance because it does not kill the bacteria 
directly and therefore exerts less pressure on the bacteria. 
The present work was in an agreement with the previous findings obtained by our group, 
who demonstrated that tetraspanin reagents (EC2 proteins and anti-tetraspanin 
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antibodies) may reduce the adherence of other Gram-negative and Gram-positive 
pathogens to host cells. Furthermore, CD9 EC2-derived peptides are also being 
investigated for their role in Salmonella adherence (Ali, 2016), Staphylococcus adherence 
(Ventress et al., 2016) and monocyte giant cell fusion (Elgawidi, 2016).  
In Chapter 3, we provided evidence demonstrating that the selective tetraspanins are 
variably expressed on keratinocyte and epithelial cell lines. Consistent with previous 
studies (Ali, 2016; Ventress, 2016), we hypothesised that each cell line may produce a 
specific type of TEM depending on the variable expression level of the tetraspanins. 
These TEMs are able to form different function specific for each cell type. 
In Chapter 4, we successfully generated a stable fluorescent-labelled P. aeruginosa and 
attempted to investigate the bacteria on a flow cytometric method that can detect the 
disruption of P. aeruginosa adhesion to host cell using tetraspanin reagents. Flow 
cytometry analysis is potentially a rapid and powerful method to investigate bacteria-host 
interaction, and many studies have reported the effectiveness of using this method, 
particularly when combined with fluorescence-labelled bacteria (Valdivia et al., 1996; 
Trouillet et al., 2011b).   
Surprisingly this method was not sensitive enough to detect the effect of tetraspanin 
reagents treatment in GFP-labelled P. aeruginosa adhesion to host cell. This was in 
agreement with the previous investigation looking at the role of tetraspanin EC2 proteins 
in Salmonella adherence to J774 cells, where flow cytometry could not detect any 
significant effects but the fluorescent microscopy obtained significant results (Ali, 2016). 
Many factors could interfere with the results from flow cytometry including using a 
specific flow cytometry machine to detect bacterial interaction, as the analysis of bacteria 
may differ depending on the growth conditions used, or the sources from which the 
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bacteria were taken (Winson and Davey, 2000). Additionally, bacteria are much smaller 
than human cells, therefore, the analysis of pathogenic bacteria poses specific challenges 
for flow cytometry. Furthermore, if the flow cytometry machine is not specifically 
designed for microbial investigation, it is necessary to determine whether it is capable of 
such analysis and then optimise its performance (Harkins and Harrigan, 2004). Therefore, 
fluorescence microscopy was used in Chapter 5 and 6 to investigate the role of 
tetraspanin treatments (anti-tetraspanin antibodies, EC2: GST proteins and CD9 EC2-
derived peptides) in GFP-labelled P. aeruginosa adherence to host cell. Here, we obtained 
the first evidence that tetraspanin reagents could significantly reduce GFP-labelled P. 
aeruginosa adherence to human cell lines, but not the internalisation. This is consistent 
with previous studies on Gram-negative and Gram-positive bacteria (Green et al., 2011b).   
Using a selection of anti-tetraspanin antibody treatments on epithelial and keratinocyte 
cells, we have shown that adherence of GFP-labelled P. aeruginosa can be significantly 
reduced. Some anti-tetraspanin antibodies had more of an effect than others, suggesting 
that some tetraspanins are more involved in P. aeruginosa association to human cells than 
others; for example, CD63 showed a great reduction in bacterial adherence to HEC1B 
cells while CD81 demonstrated no effect. However, in A549 and HaCaT cells all the anti-
tetraspanin antibody treatments appeared to result in a similar level of reduction in 
bacterial adherence. But, the number of GFP-labelled P. aeruginosa per cell was found 
to be unaffected by some tetraspanin treatments, this suggests that there is a subpopulation 
of the cells, around 40 %, on which the tetraspanin reagents are ineffective. Furthermore, 
we found that anti-CD9 and anti-CD81 protect A549 and HEC1B cells from GFP-labelled 
P. aeruginosa-induced cytotoxicity. 
Our studies have also tested the effect of recombinant tetraspanin EC2: GST proteins on 
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GFP-labelled P. aeruginosa adherence to epithelial cells and keratinocyte cells. Using 
similar concentrations of protein to those of the antibody treatment we have found that 
the GST: EC2 proteins are able to significantly reduce GFP-labelled P. aeruginosa 
adherence to a better degree than the interference of tetraspanins with antibodies, and this 
effect was not due to LPS contamination of the recombinant protein.  
In Chapter 6, CD9 EC2-derived peptides were similarly tested for their ability to reduce 
GFP-labelled P. aeruginosa adhesion to human cells. The peptides significantly reduced, 
by 50%, the adherence of GFP-labelled P. aeruginosa to epithelial and keratinocyte cells 
when compared to the scrambled control peptides which were also used as controls for 
non-specific effects. Moreover, the effect displayed by peptides was a dose dependent 
response, and peptides were active at a concentration of 3 nM. Also, the scrambled control 
peptides displayed no effect on GFP-labelled P. aeruginosa adhesion to human cells at a 
concentration of 20 nM, this indicates that the effect seen was specific for the peptides. 
However, the scrambled control peptides were found to have unspecific effect at a 
concentration of 200 nM on A549 and HEC1B cell lines but not HaCaT cells. 
These peptides may intercalate into TEMs and could work in synergy with the common 
antibiotics such as gentamicin and mupirocin to provide more antibacterial protection at 
subminimal inhibitory concentrations. P. aeruginosa first adhere to epithelial cells, and 
this adherence is mediated by Tfp. This adhesin is required for tetraspanins inhibition of 
bacterial adhesion (Cozens and Read, 2012). The Tfp can recognise CD46 (Kallstrom et 
al., 1997b) which forms complexes with the tetraspanin CD9 (Takeda et al., 2003). 
However, the exact mechanism of tetraspanin function in bacterial adhesion is still 
unclear and needs to be further investigated.  
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In addition, the effects of CD9 EC2-derived peptides on GFP-labelled P. aeruginosa 
growth and viability were tested and no effect was observed, this indicates that these 
peptides were non-toxic to the bacteria.  We also investigated the ability of selective CD9 
EC2-derived peptides to reduce GFP-labelled P. aeruginosa internalisation into A549 
cells but no effect was seen, therefore the internalisation might not be a tetraspanin 
dependent process. 
Tetraspanins are cell membrane molecules with varying important functions across the 
body. It was important to test the effects of CD9 EC2-derived peptides on cell 
metabolism, therefore MTT assay was used and no effect was seen in the pre-treated 
epithelial cells. Additionally, a slight increase in production of the cytokine IL-8 was 
observed after A549 cells were pre-treated with peptide 810.  
To summarise, we have shown that tetraspanin treatments (anti-tetraspanin antibodies- 
EC2: GST proteins and CD9 EC2-derived peptides) are capable of reducing GFP-labelled 
P. aeruginosa adhesion to epithelial and keratinocytes cells. We hypothesise that 
tetraspanins treatment may result in integration with TEMs on the cell membrane and 
through this process the peptides become capable of disordering the microdomains. This 
effect has been observed in a broad spectrum of bacterial species to different cell lines 
(Table 7.1), indicating that tetraspanin treatments may be an important new class of 
antibacterial drug development. 
7.2 Future work 
• Use high resolution microscopy such as (STORM) to identify how TEMs work 
and are organised by using either labelled antibodies or GFP-tagged tetraspanins 
in transfected cell lines. 
• Use different strains of P. aeruginosa (e.g. virulent and avirulent) to determine 
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whether the pathogenicity of these strains is related to the usage of the tetraspanin 
on human cells. 
• Use other pathogenic bacteria that have similar entry mechanism for invading 
human epithelial cells to determine if tetraspanins are involved in mediating 
adhesion in extended range of bacteria.  
• Use complex tissue culture systems that resemble lung epithelium or other tissues 
such as skin to investigate whether tetraspanins are likely to work in vitro. 
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Table 7.1 Tetraspanin treatments are effective on many bacterial species. 
Bacterium Cell line Treatments Reference 
Neisseria meningitidis 
DETROIT 
HEC1B 
MD Macrophages 
HDMECs 
 
Antibodies(CD9,63,81,151) 
Combination of antibodies 
(CD9,63,81) 
EC2: GST proteins 
(CD9,63,151) 
CD9 EC2-derived peptides 
(800,810,8001,8002,8003,8004) 
(Green et al., 
2011a). 
Escherichia coli HEC1B 
Combination of antibodies 
(CD9,63,81) 
EC2: GST proteins 
(CD9,63,151) 
(Green et al., 
2011a). 
Salmonella enterica 
HEC1B 
J774 
MD Macrophages 
 
Combination of antibodies 
(CD9,63,81) 
EC2: GST proteins 
(CD9,63,151) 
(Hassuna, 
2010; Ali, 
2016). 
Streptococcus 
pneumoniae 
HEC1B 
Combination of antibodies 
(CD9,63,81) 
(Green et al., 
2011b). 
Staphylococcus aureus 
HEC1B 
HaCaT 
EC2: GST proteins 
(CD9,63,81,151) 
CD9 EC2-derived peptides 
(800,810,8001,8005,800-Cap) 
 
(Ventress, 
2016) 
unpublished 
Pseudomonas 
aeruginosa 
A549 
HaCaT 
HEC1B 
Antibodies(CD9,63,81,151) 
EC2: GST proteins 
(CD9,63,81,151)                  
CD9 EC2-derived peptides 
(800,810,8001,8002,8003,8004,
8005,800-Cap) 
Our study 
 
• DETROIT is a human epithelial pharynx carcinoma cells line.  
• HEC1B cells are human endometrial adenocarcinoma cell line.  
• MD macrophages are monocyte derived macrophages from human peripheral blood.  
• HDMECs are human dermal microvascular endothelial cells.  
• J774 cell line is a murine macrophage tumour cell line. 
• HaCaT cells are spontaneously immortalised human keratinocyte cell line.  
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Appendix 1 
 
 
Figure A.1 The optimal time for cytokine release from peptide 810 treated and 
infected cells. 
The supernatants from peptide treated cells that were then infected with GFP-labelled P. 
aeruginosa were collected after 1, 6 and 18 hours of incubation at 37°C, 5 % CO2 for analysis 
using CBA. Results are mean ± standard error of the mean (SEM), N= 3. Data were analysed 
using One-way ANOVA with Sidak’s multisple comparisons test (vs. 1 hour incubation), *P ≤ 
0.1, **P ≤ 0.01, ***P ≤ 0.001 and ns is non-significant. 
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